documents incorporated reference document part form kannual report stockholders fiscal year parts ii ended december proxy statement annual meeting part iii stockholders held april table contents part item business item properties item legal proceedings item submission matters vote security holders part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions item principal accountant fees services part iv item exhibits financial statement schedules reports form k signatures deferral program amended restated deferred payment directors ' compensation plan offer letter computation ratios earnings fixed charges pages annual report stockholders code conduct list subsidiaries power attorney certified resolution board directors certification ceo certification cfo certification ceo certification cfotable contents part item business merck co inc company global researchdriven pharmaceutical products company discovers develops manufactures markets broad range innovative products improve human animal health directly joint ventures company sells products primarily drug wholesalers retailers hospitals clinics government agencies managed health care providers health maintenance organizations institutions companys professional representatives communicate effectiveness safety value products health care professionals private practice group practices managed care organizations january company announced plans establish medco health solutions inc medco health separate publiclytraded company august spinoff medco health effected way pro rata dividend company stockholders outstanding shares common stock medco health based letter ruling company received us internal revenue service receipt medco health shares distribution taxfree us federal income tax purposes cash received lieu fractional shares taxable product sales sales category companys products follows millions atherosclerosis hypertensionheart failure antiinflammatoryanalgesics osteoporosis respiratory vaccinesbiologicals antibacterialantifungal ophthalmologicals urology human immunodeficiency virus hiv total following spinoff companys prior period consolidated statements income cash flows related discussions restated present results medco health separately discontinued operations result spinoff product sales reflect sales medco health thirdparty sales based upon net selling price company medco health prior year amounts restated conform current year presentation presented net rebates discounts companys products include therapeutic preventive agents generally sold prescription treatment human disorders among atherosclerosis products zocor simvastatin largestselling hypertensionheart failure products significant cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide vasotec enalapril maleate antiinflammatoryanalgesics include vioxx rofecoxib arcoxia etoricoxib agents specifically inhibit cox enzyme responsible pain inflammation coxibs osteoporosis product fosamax alendronate sodium treatment prevention osteoporosis respiratory product singulair montelukast sodium leukotriene receptor antagonist treatment asthma relief symptoms seasonal allergic rhinitis vaccinesbiologicals mmr ii measles mumps rubella virus vaccine live varivax varicella virus vaccine live live virus vaccine prevention chickenpox recombivax hb hepatitis b vaccine recombinant largestselling antibacterialantifungal products includes primaxin imipenem cilastatin sodium well newer products cancidas caspofungin acetate invanz ertapenem sodium ophthalmologicals cosopt dorzolamide hydrochloride timolol maleate ophthalmic solution table contents trusopt dorzolamide hydrochloride ophthalmic solution largestselling urology product proscar finasteride treatment symptomatic benign prostate enlargement hiv products include crixivan indinavir sulfate stocrin efavirenz treatment human immunodeficiency viral infection adults primarily includes maxalt rizatriptan benzoate treatment acute migraine headaches adults propecia finasteride treatment male pattern hair loss nonpromoted products pharmaceutical animal health supply sales companys joint ventures revenue companys relationship astrazeneca lp primarily relating sales nexium esomeprazole magnesium prilosec omeprazole january us food drug administration fda approved cancidas companys oncedaily intravenous antifungal medicine treatment candidemia bloodstream infection following candida infections intraabdominal abscesses peritonitis infections within lining abdominal cavity pleural space infections infections within lining lung also january company announced fda approved singulair relief symptoms seasonal allergic rhinitis adults children young years age march fda approved emend aprepitant first member new class medicines used combination anti vomiting medicines help prevent acute delayed nausea vomiting associated initial repeat courses highly emetogenic cancer chemotherapy including highdose cisplatin also march fda approved cozaar first hypertension medicine indicated reduce risk stroke patients hypertension left ventricular hypertrophy lvh new indication based landmark losartan intervention endpoint reduction hypertension study life life study cozaar marks first time antihypertensive treatment regimen demonstrated reduction risk stroke versus another antihypertensive treatment regimen hypertensive patients lvh life study black patients hypertension lvh lower risk stroke atenolol cozaar april fda approved changes prescribing information zocor include results landmark heart protection study zocor mg recommended along diet starting dose zocor people coronary heart disease diabetes zocor mg first cholesterollowering medication proven reduce risk heart attack stroke people heart disease diabetes regardless cholesterol level acquisitions february company announced agreed acquire aton pharma inc privately held biotechnology company focusing development novel treatments cancer serious diseases see also january company wholly owned subsidiary msd japan co ltd launched tender offer acquire estimated aggregate purchase price billion remaining common shares banyu pharmaceutical co ltd banyu already october company announced close final count shares second tender offer remaining shares banyu company owned outstanding shares banyu common stock japan worlds second largest pharmaceutical market july company acquired rosetta inpharmatics inc publiclyheld washington based informational genomics company designs develops unique technologies efficiently analyze gene data predict medical compounds interact different kinds cells body joint ventures company entered agreement astra ab astra develop market astra products united states company astra formed equally owned joint venture developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining company astra restructured joint venture whereby company acquired astras interest joint venture renamed kbi inc kbi contributed kbis operating assets new us limited partnership named astra pharmaceuticals lp partnership company maintains limited partner interest partnership renamed astrazeneca lp became exclusive distributor products table contents kbi retained rights company earns certain partnership returns well ongoing revenue based sales current future kbi products partnership returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing companys share undistributed partnership gaap earnings conjunction restructuring payment million astra purchased option buy companys interest kbi products excluding companys interest gastrointestinal medicines nexium prilosec company also granted astra option shares option buy companys common stock interest kbi exercise price based net present value estimated future net sales nexium prilosec april astra merged zeneca group plc forming astrazeneca ab astrazeneca result merger exchange companys relinquishment rights future astra products existing pending us patents time merger astra paid million subject trueup calculation may require repayment portion amount merger also triggers partial redemption companys limited partner interest furthermore result merger astrazenecas option buy companys interest kbi products exercisable company right require astrazeneca purchase interest addition shares option exercisable two years astras purchase companys interest kbi products company formed joint venture johnson johnson develop market manufacture consumer health care products united states owned joint venture expanded europe canada european extension currently markets sells overthecounter pharmaceutical products france germany italy spain united kingdom significant joint venture products pepcid ac famotidine overthecounter form companys ulcer medication pepcid famotidine well pepcid complete overthecounter product combines companys ulcer medication antacids calcium carbonate magnesium hydroxide february company announced intention sell johnson johnson interest european joint venture discussed divestitures effective april company merck vaccine division connaught laboratories inc aventis pasteur agreed collaborate development marketing combination pediatric vaccines promote selected vaccines united states research marketing collaboration enables companies pool resources expedite development vaccines combining several different antigens protect children variety diseases including haemophilus influenzae type b hepatitis b diphtheria tetanus pertussis poliomyelitis combination vaccine development efforts continue agreement vaccines currently promoted company merck vaccine division pasteur mrieux connaught aventis pasteur formed joint venture market human vaccines europe collaborate development combination vaccines distribution existing european union eu european free trade association company aventis pasteur contributed among things european vaccine businesses equal shares joint venture known pasteur mrieux msd snc aventis pasteur msd snc joint venture subject monitoring eu partners made certain undertakings return exemption european competition law effective december joint venture maintains presence directly affiliates branches belgium italy germany spain france austria ireland sweden united kingdom distributors rest europe company rhnepoulenc sa combined respective animal health poultry genetics businesses form merial limited merial fullyintegrated animal health company standalone joint venture equally owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species december rhne poulenc sas interest merial acquired aventis sa corporation formed merger rhnepoulenc sa hoechst ag table contents company scheringplough corporation scheringplough entered agreements create separate equally owned partnerships develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas december company scheringplough announced worldwide expansion excluding japan cholesterolmanagement partnership october merckscheringplough pharmaceuticals msp announced fda approval zetia ezetimibe oncedaily tablet zetia mg approved use either together statin reduce ldl cholesterol total cholesterol patients high cholesterol marketing approval received october germany brand name ezetrol use alone marketed statins treatment elevated cholesterol levels following successful completion european union mutual recognition procedure mrp ezetrol launched five european countries germany united kingdom switzerland sweden netherlands completion mrp process eu member states well iceland norway grant national marketing authorization unified labeling ezetrol eu ezetrol indicated coadministration statin adjunctive therapy diet use patients primary hypercholesterolemia appropriately controlled statin alone ezetrol monotherapy indicated adjunctive therapy diet use patients primary hypercholesterolemia statin considered inappropriate tolerated addition ezetrol monotherapy indicated adjunctive therapy diet use patients homozygous familial sitosterolemia coadministered statin use patients homozygous familial hypercholesterolemia september msp submitted fda standard review new drug application nda vytorin investigational cholesterol lowering medicine contains active ingredients zetia zocor adjunctive diet reduction hypercholesterolemia elevated cholesterol levels november filing accepted fda standard review similar applications filed countries outside united states competition markets companys pharmaceutical business conducted highly competitive often highly regulated global efforts toward health care cost containment continue exert pressure product pricing access competition involves intensive search technological innovations ability market innovations effectively long standing emphasis research development company well prepared compete search technological innovations additional resources meet competition include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products joint ventures licenses refining sales marketing efforts address changing industry conditions enhance product portfolio company continues pursue external alliances earlystage latestage product opportunities including joint ventures targeted acquisitions however introduction new products processes competitors may result price reductions product replacements even products protected patents example number compounds available treat diseases typically increases time resulted slowing growth sales certain companys products addition particularly area human pharmaceutical products legislation enacted states us allows encourages instances absence specific instructions prescribing physician mandates use generic products containing active chemical innovators product rather brandname products governmental pressures toward dispensing generic products significantly reduced sales certain companys products longer protected patents vasotec vaseretic enalapril maleate combination hydrochlorothiazide us rights sold prinivil lisinopril prinzide lisinopril combination hydrochlorothiazide pepcid mevacor lovastatin slowed growth certain products distribution company sells human health products primarily drug wholesalers retailers hospitals clinics government agencies managed health care providers health maintenance organizations institutions vaccines also sold directly physicians companys professional representatives table contents communicate effectiveness safety value companys products health care professionals private practice group practices managed care organizations fourth quarter company implemented new distribution program us wholesalers moderate fluctuations sales caused wholesaler investment buying improve efficiencies distribution company pharmaceutical products new program lowered previous limits average monthly purchases company pharmaceutical products us customers overall implementation new us wholesaler distribution program estimated million unfavorable impact consolidated revenues estimated million unfavorable effect zocor sales raw materials raw materials supplies normally available quantities adequate meet needs companys business government regulation investigation pharmaceutical industry subject global regulation regional country state local agencies particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states food drug administration modernization act passed culmination comprehensive legislative reform effort designed streamline regulatory procedures within fda improve regulation drugs medical devices food legislation principally designed ensure timely availability safe effective drugs biologics expediting premarket review process new products key provision legislation reauthorization prescription drug user fee act permits continued collection user fees prescription drug manufacturers augment fda resources earmarked review human drug applications helps provide resources necessary ensure prompt approval safe effective new drugs united states government made significant progress expanding health care access enacting medicare prescription drug improvement modernization act signed law december statute adds prescription drug coverage medicare beginning voluntary drug discount card medicare beneficiaries effective june implementation new benefit support companys goal improving access medicines expanding insurance coverage preserving marketbased incentives pharmaceutical innovation time benefit designed assure prescription drug costs controlled competitive pressures encouraging appropriate use medicines company taken leadership role contributing success new medicareendorsed discount cards offering provide medicines free lowincome medicare beneficiaries exhaust transitional assistance allowance medicareendorsed drug discount cards action consistent companys longstanding patient assistance program provides free medicines patients united states lack drug coverage afford medicines addressing cost containment outside medicare company made continuing effort demonstrate medicines help save costs overall patient health care addition pricing flexibility across companys product portfolio encouraged growing use medicines mitigated effects increasing cost pressures many years pharmaceutical industry federal state oversight approval process new drugs drug safety advertising promotion drug purchasing reimbursement programs formularies variously review company believes continue able conduct operations including introduction new drugs market regulatory environment one type federal initiative contain federal health care spending prospective capitated payment system first implemented reduce rate growth medicare reimbursement hospitals system establishes advance flat rate reimbursement health care patients payer fiscally responsible type payment system cost containment systems widely used public private payers caused hospitals health maintenance organizations customers company costconscious table contents treatment decisions including decisions regarding medicines made available patients company continues work private federal employers slow increases health care costs companys efforts demonstrate medicines help save costs areas pricing flexibility across product portfolio encouraged use companys medicines helped offset effects increasing cost pressures also federal state governments pursued methods directly reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities disproportionate share hospitals hospitals meeting certain criteria provide minimum discounts defined nonfederal average manufacturer price purchases certain components federal government department veterans affairs department defense initiatives states seek rebates beyond minimum required medicaid legislation cases patients beyond eligible medicaid federal vaccines children entitlement program us centers disease control prevention cdc funds purchases recommended pediatric vaccines public sector price immunization medicaideligible uninsured native american certain underinsured children company awarded cdc contracts supply million pediatric vaccines program monovalent component certain vaccines outside united states company encounters similar regulatory legislative issues countries business primary thrust governmental inquiry action toward determining drug safety effectiveness often mechanisms controlling prices prescription drugs profits prescription drug companies eu adopted directives concerning classification labeling advertising wholesale distribution approval marketing medicinal products human use companys policies procedures already consistent substance directives consequently believed material effect companys business company subject jurisdiction various regulatory agencies therefore subject potential administrative actions actions may include seizures products civil criminal sanctions certain circumstances company may deem advisable initiate product recalls company believes able compete effectively within environment addition certain countries within eu recognizing economic importance researchbased pharmaceutical industry value innovative medicines society working industry representatives european commission proposals complete single market pharmaceuticals improve competitive climate variety means including market deregulation increasing amount focus privacy issues countries around world including united states eu united states federal state governments pursued legislative regulatory initiatives regarding patient privacy including federal recently issued state privacy regulations concerning health information affected companys operations patents trademarks licenses patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance date grant legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage patent portfolios developed products introduced company normally provide market exclusivity basic patents effect following major products united states arcoxia cancidas comvax haemophilus b conjugate hepatitis b recombinant vaccine cosopt cozaar crixivan emend fosamax table contents hyzaar invanz maxalt pedvaxhib haemophilus b conjugate vaccine primaxin propecia proscar recombivax hb singulair timopticxe timolol maleate ophthalmic gel forming solution trusopt vioxx zocor basic patent also effect united states zetia developed merckscheringplough pharmaceuticals partnership basic patent also effect sustivastocrin efavirenz bristolmyers squibb exclusive license company sells sustiva united states canada certain european countries company markets stocrin countries throughout world basic patent aggrastat tirofiban hydrochloride united states divested product company retains basic patents aggrastat outside united states zocor lost basic patent protection canada certain countries europe including united kingdom germany company experienced decline zocor sales countries zocor lose market exclusivity united states company expects decline us zocor sales fda modernization act modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant exclusivity provisions reauthorized october best pharmaceuticals children act passed january fda granted additional six months market exclusivity united states fosamax february fosamax weekly january addition fda granted additional six months market exclusivity united states trusopt october vioxx six months beyond patent termination expiration product patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv united states market exclusivity may available federal law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset general increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalties received patent knowhow licenses rights amounted million company also paid royalties amounting million patent knowhow licenses holds divestitures february company announced signed definitive agreement johnson johnson johnson johnson buy companys percent equity stake european nonprescription pharmaceuticals joint venture company sold us rights aggrastat tirofiban hydrochloride injection guilford pharmaceuticals inc guilford including basic us product patents process patents product table contents company sold us rights vasotec vaseretic vasotec iv injection enalaprilat biovail laboratories incorporated biovail subsidiary biovail corporation time companys canadian subsidiary merck frosst canada co merck frosst biovail entered supply agreement merck frosst agreed supply biovail minimum five years bulk tablets formulated enalapril maleate enalapril maleate combination hydrochlorothiazide distribution biovail united states vasotec vaseretic basic product patents vasotec vaseretic expired united states prior transactions research development companys business characterized introduction new products new uses existing products strong research development program approximately people employed companys research activities expenditures companys research development programs billion billion billion estimated increase lowteen percentage growth rate fullyear expense company maintains ongoing commitment research broad range therapeutic areas clinical development support new products total expenditures period exceeded billion compound annual growth rate company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development projects related human health carried various fields bacterial fungal viral infections cardiovascular disease atherosclerosis cancer diabetes obesity neurodegenerative disease psychiatric disease pain inflammation immunology respiratory diseases ophthalmology respiratory diseases osteoporosis menwomen health programs endoparasitic ectoparasitic diseases companion animal diseases production improvement development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug may marketed united states recorded data preclinical clinical experience included nda biological product license application pla fda required approval development certain products also subject government regulations covering safety efficacy united states many foreign countries assurance compound result particular program obtain regulatory approvals necessary marketed companys latestage pipeline candidates include novel vaccines human papillomavirus hpv pain associated shingles rotateq vaccine rotavirusa highly contagious virus common cause severe gastroenteritis infants young children company expects file plas fda three novel vaccine candidates second half competing claims intellectual property hpv field company confident claims delay companys program company expects submit pla fda proquad vaccine pediatric combination vaccine measles mumps rubella chickenpox second half company also studying dpiv inhibitor glucoselowering mechanism used alone combination treatment type ii diabetes company plans enter phase iii clinical trials investigational compound second quarter expects submit nda fda companys earlystage pipeline includes candidates following areas diabetes obesity alzheimers disease respiratory disease coronary heart disease rheumatoid arthritis vaccines company supplements internal research aggressive licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies company completed significant transactions including research collaborations preclinical clinical compounds technology transactions transactions completed include agreements table contents following companies genpath cancer amrad respiratory disease neurogen pain actelion cardiovascular disease february company announced entered agreement h lundbeck lundbeck develop commercialize united states gaboxadol compound licensed lundbeck third party currently phase iii development treatment sleep disorders terms agreement lundbeck receive initial payment million million additional milestone payments company lundbeck jointly complete ongoing phase iii clinical program company funding majority remaining development activities company anticipates file nda fda late mid following fda approval companies plan copromote gaboxadol united states lundbeck receive share gaboxadol sales united states february company announced agreed acquire aton pharma inc aton privately held biotechnology company focusing development novel treatments cancer serious diseases consideration acquisition consist upfront contingent payments based upon regulatory filing approval sales products atons clinical pipeline histone deacetylase inhibitors represents class antitumor agents potential efficacy based novel mechanism action atons lead product candidate known suberoylanilide hydroxamic acid extensively studied phase clinical trials currently phase ii clinical trials treatment cutaneous tcell lymphoma company expects complete acquisition aton first quarter chart reflects companys research pipeline march candidates shown phase iii include specific products candidates shown phase ii include advanced compound specific mechanism given therapeutic area backup compounds regardless phase development additional indications therapeutic areas additional line extensions formulations inline products shown preclinical areas shown company initiated good laboratory practices glp studies compounds mechanisms distinct phase ii companys programs generally designed focus development novel medicines address large unmet medical needs table contents preclinical phase phase ii phase iii diabetes diabetes c obesity vaccines atherosclerosis obesity c pediatric combination c alzheimers disease vaccine parkinsons disease c c proquad atherosclerosis urinary incontinence rotavirus pain c c rotateq alzheimers disease respiratory disease shingles anxiety c c zoster vaccine c postoperative nausea human papillomavirus osteoporosis multiple sclerosis vomiting hpv vaccine c c cancer pain vaccines diabetes c pediatric combination mk q rheumatoid arthritis psychiatric disease c sleep disorders glaucoma respiratory disease mk gaboxadol c antibacterial rheumatoid arthritis c vaccines c aids c vaccines hiv vaccine submissions cardiovascular arthritis analgesia vytorin arcoxia ezetimibe simvastatin submitted q submitted q february company announced discontinued phase ii clinical trials lead gabaa agonist compound treatment generalized anxiety company continuing research field anxiety ongoing study gaba agonist molecules timing development molecules certain april company announced discontinuing development lead phosphodiesterase pde inhibitor compound phase ii clinical trials treatment asthma chronic obstructive pulmonary disease copd company continuing research field asthma copd ongoing study pde inhibitor molecules timing development molecules certain august company announced put phase clinical trials lead hiv integrase inhibitor compound hold company also continuing research field integrase inhibitors ongoing study integrase inhibitors timing development molecules certain november company announced discontinuing phase iii clinical development program substance p antagonist investigational product mk treatment depression phase iii clinical program halted compound failed demonstrate efficacy treatment depression company remains committed neuroscience research programs also november company announced discontinuing phase iii clinical development program investigational product mk treatment diabetes company table contents developing mk collaboration kyorin pharmaceutical co ltd clinical program halted recent findings companys longterm safety assessment program identified rare form malignant tumors mice clinical relevance findings humans unknown company continuing commitment diabetes research currently studying dpiv inhibitor diabetes company plans enter phase iii clinical trials investigational compound second quarter february banyu announced change timing respect filing japan nda rofecoxib vioxx press release banyu stated reviewing clinical data accumulated date recommendation organization pharmaceutical safety research banyu agreed conduct additional studies japanese patients support nda filing result decision nda filing originally planned take place end march delayed banyu stated conduct additional studies appropriate support filing product december company submitted nda fda arcoxia companys nda seeks indications arcoxia treatment osteoarthritis rheumatoid arthritis chronic low back pain acute pain dysmenorrhea acute gouty arthritis ankylosing spondylitis painful condition spine january arcoxia launched countries worldwide europe latin america asia pacific region fda informed company fda considers january effective submission date nda fiscal year fees different medicine received december fda informed company unless company otherwise notified nda accepted filing march november european unions committee proprietary medicinal products concluded comprehensive review cox selective inhibitor class includes vioxx arcoxia confirmed medicines positive balance benefits risks french transparency commission whose responsibilities include recommending drug reimbursement levels france review retained assessment vioxx provides modest level improvement relative nonsteroidal antiinflammatory drugs terms safety product service marks appearing type form different surrounding text trademarks service marks owned licensed merck co inc subsidiaries affiliates including zetia trademark owned entity merckscheringplough pharmaceuticals partnership except noted cozaar hyzaar registered trademarks ei du pont de nemours company wilmington de prilosec nexium trademarks astrazeneca group us trademarks vasotec vaseretic owned biovail laboratories incorporated us trademark aggrastat owned guilford pharmaceuticals inc employees end company employees worldwide employed united states including puerto rico approximately worldwide employees company represented various collective bargaining groups company accelerated efforts fundamentally lower cost structure companywide initiatives october company announced reduction positions expected completed complete cost reductions expected generate annual savings payroll benefits costs million starting environmental matters company believes compliance material respects applicable environmental laws regulations company incurred capital expenditures approximately million environmental protection facilities company also remediating environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities table contents million estimated million years amounts consider potential recoveries insurers parties company taken active role identifying providing costs managements opinion liabilities environmental matters probable reasonably estimable accrued although possible predict certainty outcome environmental matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess provided result material adverse effect companys financial position results operations liquidity capital resources cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forwardlooking statements subject risks uncertainties one identify forwardlooking statements use words expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product approvals development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially although possible predict identify factors may include following generic competition product patents several products recently expired united states countries including product patents mevacor us prinivil prinzide us vaseretic us zocor lost basic patent protection canada certain countries europe including united kingdom germany company experienced decline zocor sales countries zocor lose market exclusivity united states company expects decline us zocor sales addition us patent covering omeprazole active ingredient prilosec company supplies exclusively astrazeneca lp expired trial court held october one generic companys omeprazole product infringe companys formulation patents respect prilosec agreement astrazeneca company receives supply payments predetermined rates us sales certain products astrazeneca notably prilosec nexium increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general company previously announced fourth quarter taken actions lower cost structure including elimination positions actions continue changes government laws regulations enforcement thereof affecting companys business efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales table contents legal factors including product liability claims antitrust litigation governmental investigations environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities increased focus privacy issues countries around world including united states eu united states federal state governments pursued legislative regulatory initiatives regarding patient privacy including federal recently issued state privacy regulations concerning health information affected companys operations changes tax laws including changes related taxation foreign earnings well impact legislation capping ultimately repealing section internal revenue code relating earnings companys puerto rican operations changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board securities exchange commission adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties geographic area segment information companys operations principally managed products basis one reportable segment merck pharmaceutical segment includes products marketed either directly joint ventures merck pharmaceutical products consist therapeutic preventive agents sold prescription treatment prevention human disorders companys operations outside united states conducted primarily subsidiaries sales worldwide subsidiaries outside united states sales respectively companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions recent years company expanding operations countries located latin america middle east africa eastern europe asia pacific changes government policies economic conditions making possible company earn fair returns business developing areas sometimes less stable offers important opportunities growth time financial information geographic areas operating segments companys business incorporated reference pages beginning caption segment reporting companys annual report stockholders available information companys internet website address wwwmerckcom company make available free charge investor information portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section table contents securities exchange act amended soon reasonably practicable reports electronically filed furnished securities exchange commission company 's corporate governance guidelines charters board directors ' six standing committees available company 's website wwwmerckcomaboutcorporategovernance information available print stockholder requests company item properties companys corporate headquarters located whitehouse station new jersey companys pharmaceutical business conducted divisional headquarters located upper gwynedd west point pennsylvania principal research facilities human health products located rahway new jersey west point company also production facilities human health products nine locations united states puerto rico branch warehouses provide services throughout country outside united states subsidiaries company owns interest manufacturing plants properties australia canada japan singapore south africa countries western europe central south america asia capital expenditures million compared million united states amounted million million abroad expenditures amounted million million company subsidiaries principal facilities manufacturing plants titles consider satisfactory company considers properties good operating condition machinery equipment well maintained plants manufacture products suitable intended purposes capacities projected capacities adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products item legal proceedings company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions beginning company named number antitrust suits certain certified class actions instituted nations retail pharmacies consumers several states alleging antitrust violations actions except pending state courts consolidated pretrial purposes federal court chicago illinois company several defendants settled federal class action represented single largest group claims since time company settled substantially remaining cases satisfactory terms company engaged conspiracy admission wrongdoing made included settlement agreements feasible predict final outcome remaining cases opinion company proceedings ultimately result liability would material adverse effect companys financial position results operations liquidity previously disclosed company advised us department justice investigating marketing selling activities company pharmaceutical manufacturers connection investigation previously disclosed government served subpoena company production documents related company marketing sales activities subpoena seeks substantially information government previously sought company working government respond appropriately subpoena informational requests company also received civil investigative demand cid attorney general texas cid seeks production documents information regarding companys marketing selling activities relating texas company working texas attorney generals office respond appropriately cid previously disclosed company joined ongoing litigation alleging manipulation pharmaceutical manufacturers average wholesale prices awp sometimes used calculations determine public private sector reimbursement levels judicial panel multidistrict litigation table contents ordered transfer consolidation pending federal awp cases federal court boston massachusetts plaintiffs filed one consolidated class action complaint aggregated claims previously filed various federal district court actions also expanded number manufacturers include like company defendants prior pending case may court granted companys motion dismiss consolidated class action dismissed company class action case subsequent companys dismissal plaintiffs filed amended consolidated class action complaint name company defendant company thirty pharmaceutical manufacturers remain defendants three similar complaints pending federal court massachusetts filed new york counties suffolk rockland westchester company believes lawsuits without merit vigorously defending previously disclosed january us department justice notified federal court new orleans louisiana going intervene pending federal false claims act case filed seal december company court issued order unsealing complaint filed physician louisiana ordered complaint served complaint alleges companys discounting pepcid certain louisiana hospitals led increases costs medicaid company believes complaint without merit vigorously defend federal state lawsuits involving numerous individual claims well putative class actions filed company respect vioxx lawsuits also name defendant pfizer inc markets competing product certain lawsuits include allegations regarding gastrointestinal bleeding cardiovascular events kidney damage lawsuits filed federal courts well number state courts cases jurisdictions proceeding separately actions filed state courts california new jersey transferred single judge state coordinated proceedings company anticipates one lawsuits various jurisdictions may go trial first half litigation inherently subject uncertainties assurance given outcome given trial however company believes lawsuits without merit vigorously defend number purported class action lawsuits filed several individual shareholders united states district court eastern district louisiana naming defendants company several current former officers company alleging defendants made false misleading statements regarding companys drug vioxx violation federal securities laws plaintiffs request certification class purchasers companys common stock may october seek unspecified compensatory damages costs suit including attorney fees company believes lawsuits without merit vigorously defend company party claims brought consumer protection act united kingdom allege certain children suffer variety conditions result vaccinated various bivalent vaccines measles rubella andor trivalent vaccines measles mumps rubella including companys mmr ii pharmaceutical companies also sued claimants allege various adverse consequences including autism without inflammatory bowel disease epilepsy diabetes encephalitis encephalopathy chronic fatigue syndrome connection claims eight lead cases selected trial scheduled commence april two company six pharmaceutical companies trial eight cases initially limited issues causation defect conditions autistic spectrum disorders without inflammatory bowel disease early september legal services commission announced decision withdraw public funding litigation brought claimants decision confirmed appeal funding review committee september april trial date vacated claims stayed pending outcome february hearing judicial review funding withdrawal decision company believes lawsuits without merit vigorously defend company also party individual class action product liability lawsuits claims united states involving pediatric vaccines ie hepatitis b vaccine haemophilus influenza type b vaccine table contents contained thimerosal preservative used vaccines defendants include vaccine manufacturers produced pediatric vaccines containing thimerosal well manufacturers thimerosal actions plaintiffs allege among things suffered neurological injuries result thimerosal introduced developing bodies company successful many cases either dismissed stayed ground national vaccine injury compensation program nvicp prohibits person filing maintaining civil action seeking damages vaccine manufacturer vaccinerelated injuries unless petition first filed united states court federal claims number similar cases mmr ii alone andor thimerosalcontaining vaccines filed united states court federal claims nvicp determination first general causation issues company believes lawsuits claims without merit vigorously defend proceedings party time time generic manufacturers pharmaceutical products file abbreviated new drug applications andas fda seeking market generic forms company products prior expiration relevant patents owned company generic pharmaceutical manufacturers submitted andas fda seeking market united states generic form fosamax prilosec vioxx prior expiration companys astrazenecas case prilosec patents concerning products generic companies andas generally include allegations noninfringement invalidity unenforceability patents generic manufacturers received fda approval market generic form prilosec company filed patent infringement suits federal court companies filing andas generic alendronate rofecoxib astrazeneca company filed patent infringement suits federal court companies filing andas generic omeprazole similar patent challenges exist certain foreign jurisdictions company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration dates patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products trial united states respect alendronate daily product concluded november november decision issued us district court delaware finding companys patent valid infringed october us court appeals federal circuit affirmed validity infringement companys basic us patent covering use alendronate form request rehearing denied trial united states involving alendronate weekly product held march august us district court delaware upheld validity companys us patent covering weekly administration alendronate result courts decision patent valid infringed teva pharmaceuticals usa incs teva abbreviated new drug application filing courts decision appealed teva january high court justice england wales held patents company protecting alendronate daily weekly products invalid united kingdom november court appeals england wales affirmed ruling high court justice england wales protection generic companies referencing companys data weekly alendronate united kingdom may available provisions law grant period exclusivity original submitter data generic company sought judicial review decision licensing authority united kingdom rely upon companys weekly alendronate data seek approval generic alendronate mg product ten years approval companys weekly alendronate product granted company served interested party intends take appropriate action protect rights case omeprazole trial court united states rendered opinion october upholding validity companys astrazenecas patents covering stabilized formulation omeprazole ruling one defendants omeprazole product infringe patents three defendants products found infringe formulation patents december us court appeals federal circuit affirmed decision trial court respect certain generic manufacturers omeprazole products trial date yet set table contents case rofecoxib anda filed including allegations noninfringement invalidity unenforceability companys rofecoxib patents previously disclosed company filed patent infringement lawsuit district court delaware august trial set october previously disclosed company named defendant number purported class action lawsuits consolidated single judge shareholder derivative action involve claims related companys revenue recognition practice retail copayments paid individuals medco health provides pharmaceutical benefits class action lawsuit amended add claims company medco health certain officers directors relating rebates received medco health medco healths independent status shareholder derivative action amended add arthur andersen llp defendant add certain new allegations relate claims certain individual defendants breached fiduciary duty failing prevent conduct issue previously disclosed gruer cases discussed antitrust claims pending northern district illinois qui tam actions us attorneys office eastern district pennsylvania intervened medco health complaint seeks monetary damages company directors defendants lawsuit unspecified amount well injunctive relief part spinoff medco health medco health assumed responsibility portion potential damages settlement payments paid connection litigation company believes lawsuits without merit vigorously defend prior spinoff medco health company medco health agreed settle class action basis series lawsuits asserting violations employee retirement income security act erisa company medco health certain plaintiffs counsel filed settlement agreement federal district court new york cases commenced number plaintiffs including participants number pharmaceutical benefit plans medco health pharmacy benefit manager well trustees plans consolidated proposed class settlement agreed plaintiffs five cases gruer cases filed medco health company proposed settlement company medco health agreed pay total million medco health agreed modify certain business practices continue certain specified business practices period five years financial compensation intended benefit members settlement class includes erisa plans medco health administered pharmacy benefit time since december court preliminarily approved settlement held hearing hear objections fairness proposed settlement class member representatives currently certain class member plans indicated participate settlement court yet approved settlement determined number class member plans properly elected participate settlement approved settlement becomes final district court grants final approval appeals resolved medco health company agreed proposed settlement order avoid significant cost distraction protracted litigation gruer cases similar claims pending pharmaceutical benefit managers alleged medco health erisa fiduciary company partyininterest within meaning erisa plaintiffs asserted company medco health breached duties engaged prohibited transactions result filling prescriptions companys drugs increase companys market share among things plaintiffs demanded medco health company disgorge unlawfully obtained profits relief addition among cases consolidated new york one plaintiff also alleged based essentially factual allegations gruer cases medco health company violated federal state racketeering laws different plaintiff seeking represent california citizens alleged medco health company violated california unfair competition law attorney one plaintiffs indicated may assert claims medco health company others allege violations sherman act clayton act various state antitrust laws based alleged conspiracies suppress price competition unlawful combinations allegedly resulting higher pharmaceutical prices table contents spinoff medco health medco health assumed substantially liability exposure matters discussed foregoing three paragraphs company believes cases defended medco health without merit december virginia department environmental quality vadeq issued notice violation companys elkton virginia facility air permit limit exceedances reported facility result performance testing process train company currently discussions vadeq believes discussions result capital improvements together monetary sanctions immaterial exceed company party number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying providing costs amounts include reduction anticipated recoveries cleanup costs insurers former site owners operators recalcitrant potentially responsible parties various legal proceedings principally product liability intellectual property suits involving company pending feasible predict outcome proceedings proceedings discussed opinion company proceedings either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company addition time time federal state regulators seek information practices pharmaceutical industry feasible predict outcome requests information company expect inquiries material adverse effect financial position liquidity results operations company item submission matters vote security holders applicable table contents executive officers registrant march raymond v gilmartin age june chairman board since november president chief executive officer david w anstice age january president human health responsible companys prescription drug business japan latin america canada australia new zealand companys joint venture relationship scheringplough march president americas us human health responsible one two prescription drug divisions comprising us human health well companys prescription drug business canada latin america companys joint venture relationship scheringplough january president human healththe americas responsible companys human health business united states canada latin america marcia j avedon age january senior vice president human resources september vice president talent management organization effectiveness prior september dr avedon held several senior human resources positions honeywell international diversified manufacturing technology company richard clark age june president merck manufacturing division responsible companys manufacturing information services operational excellence organizations worldwide january chairman president chief executive officer medco health solutions inc medco health formerly whollyowned subsidiary company january president medco health june executive vice presidentchief operating officer medco health celia colbert age january vice president secretary since september assistant general counsel since november caroline dorsa age august vice president treasurer responsible companys treasury tax functions providing financial support merck manufacturing merck research laboratories divisions well human resources september vice president treasurer responsible companys treasury tax functions providing financial support asia pacific division february vice president treasurer since january responsible companys treasury tax functions table contents kenneth c frazier age december senior vice president general counsel responsible legal public affairs functions merck company foundation notforprofit charitable organization affiliated company january vice president deputy general counsel richard c henriques jr age august vice president controller responsible corporate controllers group providing financial support human health operations united states canada latin america europe middle east africa japan australianew zealand merck vaccine division mvd november vice president controller responsible corporate controllers group providing financial support us human health canada latin america americas mvd february vice president controller since january responsible corporate controllers group providing financial support americas peter kim age january president merck research laboratories mrl february executive vice president research development mrl prior february dr kim served member whitehead institute professor biology massachusetts institute technology investigator howard hughes medical institute judy c lewent age january executive vice president chief financial officer president human health asia responsible financial corporate development functions internal auditing corporate licensing companys prescription drug business asia north asia south companys joint venture relationships merck capital ventures llc subsidiary company february executive vice president chief financial officer responsible financial corporate development functions internal auditing corporate licensing companys joint venture relationships merck capital ventures llc november senior vice president chief financial officer responsible financial corporate development functions internal auditing corporate licensing companys joint venture relationships merck capital ventures llc january senior vice president since january chief financial officer since april responsible financial corporate development functions internal auditing companys joint venture relationships adel mahmoud age may president merck vaccines november executive vice president merck vaccines table contents margaret g mcglynn age january president us human health responsible one two prescription drug divisions hospital specialty product franchises comprising us human health ushh managed care group ushh august executive vice president customer marketing sales ushh november senior vice president worldwide human health marketing bradley sheares age january president us human health responsible one two prescription drug divisions primary care product franchises comprising us human health ushh march president us human health responsible one two prescription drug divisions hospital specialty product franchises comprising ushh july vice president hospital marketing sales ushh joan e wainwright age january vice president public affairs june vice president corporate communications public affairs prior june ms wainwright deputy commissioner communications us social security administration per woldolsen age january president human healtheurope middle east africa responsible companys prescription drug business europe middle east africa worldwide human health marketing officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer board family relationships among officers listed table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities required information market information dividends incorporated reference companys annual report stockholders required information number holders companys common stock incorporated reference companys annual report stockholders item selected financial data information required item incorporated reference data last five fiscal years company included results year yearend position selected financial data table companys annual report stockholders item managements discussion analysis financial condition results operations information required item incorporated reference pages companys annual report stockholders item quantitative qualitative disclosures market risk information required item incorporated reference pages beginning caption analysis liquidity capital resources companys annual report stockholders item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income retained earnings comprehensive income cash flows three years period ended december report dated february pricewaterhousecoopers llp independent auditors incorporated reference pages respectively companys annual report stockholders b supplementary data selected quarterly financial data incorporated reference data contained condensed interim financial data table companys annual report stockholders item changes disagreements accountants accounting financial disclosure applicable item controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended effective significant changes internal control financial reporting period covered report materially affected reasonably likely materially affect companys internal control financial reporting table contents part iii item directors executive officers registrant required information directors nominees incorporated reference pages companys proxy statement annual meeting stockholders held april information executive officers set forth part document pages required information audit committee financial expert incorporated reference heading financial expert audit committee companys proxy statement annual meeting stockholders held april required information identification audit committee incorporated reference pages caption board committees companys proxy statement annual meeting stockholders held april required information compliance section securities exchange act incorporated reference caption section beneficial ownership reporting compliance companys proxy statement annual meeting stockholders held april company adopted code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer code conduct available companys website wwwmerckcomaboutcorporategovernance print stockholder requests company intends post website amendments waivers code conduct item executive compensation information required item incorporated reference pages caption compensation directors caption compensation chief executive officer pages beginning caption annual benefits payable merck co inc retirement plans caption compensation committee interlocks insider participation companys proxy statement annual meeting stockholders held april item security ownership certain beneficial owners management related stockholder matters information respect securities authorized issuance equity compensation plans incorporated reference pages beginning caption equity compensation plan information companys proxy statement annual meeting stockholders held april information respect security ownership certain beneficial owners management incorporated reference pages caption security ownership certain beneficial owners management companys proxy statement annual meeting stockholders held april item certain relationships related transactions information required item incorporated reference caption relationships outside firms caption indebtedness management companys proxy statement annual meeting stockholders held april item principal accountant fees services information required item incorporated reference pages beginning caption preapproval policy services independent auditors companys proxy statement annual meeting stockholders held april table contents part iv item exhibits financial statement schedules reports form k documents filed part financial statements following consolidated financial statements report independent auditors incorporated herein reference companys annual report stockholders noted document consolidated statement income years ended december consolidated statement retained earnings years ended december consolidated statement comprehensive income years ended december consolidated balance sheet december consolidated statement cash flows years ended december notes consolidated financial statements report pricewaterhousecoopers llp independent auditors financial statement schedules schedules omitted either required applicable financial statements affiliates carried equity basis omitted considered individually aggregate affiliates constitute significant subsidiary exhibits exhibit number description master restructuring agreement dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june restated certificate incorporation merck co inc september incorporated reference form q quarterly report period ended september bylaws merck co inc amended effective february incorporated reference form q quarterly report period ended march executive incentive plan amended effective february incorporated reference annual report fiscal year ended december management contract compensatory plan arrangement table contents exhibit number description base salary deferral plan adopted october effective january incorporated reference form k annual report fiscal year ended december merck co inc deferral program amended restated november incentive stock plan amended effective february incorporated reference annual report fiscal year ended december incentive stock plan amended november incorporated reference form q quarterly report period ended june incentive stock plan amended restated july incorporated reference form q quarterly report period ended september incentive stock plan amended july incorporated reference registration statement form nonemployee directors stock option plan amended restated february incorporated reference annual report fiscal year ended december nonemployee directors stock option plan amended april incorporated reference form q quarterly report period ended june nonemployee directors stock option plan amended april incorporated reference form q quarterly report period ended june supplemental retirement plan amended effective january incorporated reference annual report fiscal year ended december retirement plan directors merck co inc amended restated june incorporated reference form q quarterly report period ended june plan deferred payment directors compensation amended restated november limited liability company agreement merck capital ventures llc dated november incorporated reference annual report fiscal year ended december offer letter merck co inc peter kim dated december amended restated license option agreement dated july astra ab astra merck inc incorporated reference form q quarterly report period ended june management contract compensatory plan arrangement table contents exhibit number description kbi shares option agreement dated july among astra ab merck co inc merck holdings inc incorporated reference form q quarterly report period ended june kbie asset option agreement dated july among astra ab merck co inc astra merck inc astra merck enterprises inc incorporated reference form q quarterly report period ended june kbi supply agreement dated july astra merck inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june second amended restated manufacturing agreement dated july among merck co inc astra ab astra merck inc astra usa inc incorporated reference form q quarterly report period ended june limited partnership agreement dated july kb usa lp kbi sub inc incorporated reference form q quarterly report period ended june distribution agreement dated july astra merck enterprises inc astra pharmaceuticals lp incorporated reference form q quarterly report period ended june agreement incorporate defined terms dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp incorporated reference form q quarterly report period ended june computation ratios earnings fixed charges annual report stockholders portions incorporated reference document deemed filed code conduct values standards list subsidiaries consent independent accountants contained report power attorney certified resolution board directors rule ada certification chief executive officer rule ada certification chief financial officer section certification chief executive officer section certification chief financial officer table contents none instruments defining rights holders longterm debt company subsidiaries exhibit number filed since total amount securities authorized instruments taken individually exceed total assets company subsidiaries consolidated basis company agrees furnish copy instruments commission upon request copies exhibits may obtained stockholders upon written request directed stockholder services department merck co inc po box ws ab whitehouse station new jersey accompanied check amount payable merck co inc cover processing mailing costs b reports form k threemonth period ended december company furnished one current report form k item regulation fd disclosure item results operations financial condition report dated furnished october regarding earnings third quarter certain supplemental information three current reports form k item regulation fd disclosure report dated furnished december regarding financial guidance ii report dated furnished december regarding annual business briefing presentations iii report dated furnished december regarding companys annual business briefing analysts table contents signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized merck co inc dated march raymond v gilmartin chairman board president chief executive officer celia colbert celia colbert attorneyinfact pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signatures title date raymond v gilmartin chairman board march president chief executive officer principal executive officer director judy c lewent executive vice president chief march financial officer president human health asia principal financial officer richard c henriques jr vice president controller principal accounting officer march lawrence bossidy director march william g bowen director march johnnetta b cole director march william daley director march william b harrison jr director march william n kelley director march heidi g miller director march thomas e shenk director march samuel thier director march wendell p weeks director march peter c wendell director march celia colbert signing name hereto hereby sign document pursuant powers attorney duly executed persons named filed securities exchange commission exhibit document behalf persons capacities date stated persons including majority directors company celia colbert celia colbert attorneyinfact table contents exhibit consent independent accountants hereby consent incorporation reference registration statements form nos form nos merck co inc report dated february relating consolidated financial statements appears annual report stockholders incorporated annual report pricewaterhousecoopers llp florham park new jersey march table contents exhibit index exhibit number description master restructuring agreement dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june restated certificate incorporation merck co inc september incorporated reference form q quarterly report period ended september bylaws merck co inc amended effective february incorporated reference form q quarterly report period ended march executive incentive plan amended effective february incorporated reference form k annual report fiscal year ended december base salary deferral plan adopted october effective january incorporated reference annual report fiscal year ended december merck co inc deferral program amended restated november incentive stock plan amended effective february incorporated reference annual report fiscal year ended december incentive stock plan amended november incorporated reference form q quarterly report period ended june incentive stock plan amended restated july incorporated reference form q quarterly report period ended september incentive stock plan amended july incorporated reference registration statement form nonemployee directors stock option plan amended restated february incorporated reference annual report fiscal year ended december nonemployee directors stock option plan amended april incorporated reference form q quarterly report period ended june nonemployee directors stock option plan amended april incorporated reference form q quarterly report period ended june supplemental retirement plan amended effective january incorporated reference annual report fiscal year ended december management contract compensatory plan arrangement table contents exhibit number description retirement plan directors merck co inc amended restated june incorporated reference form q quarterly report period ended june plan deferred payment directors compensation amended restated november limited liability company agreement merck capital ventures llc dated november incorporated reference annual report fiscal year ended december offer letter merck co inc peter kim dated december amended restated license option agreement dated july astra ab astra merck inc incorporated reference form q quarterly report period ended june kbi shares option agreement dated july among astra ab merck co inc merck holdings inc incorporated reference form q quarterly report period ended june kbie asset option agreement dated july among astra ab merck co inc astra merck inc astra merck enterprises inc incorporated reference form q quarterly report period ended june kbi supply agreement dated july astra merck inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission incorporated reference form q quarterly report period ended june second amended restated manufacturing agreement dated july among merck co inc astra ab astra merck inc astra usa inc incorporated reference form q quarterly report period ended june limited partnership agreement dated july kb usa lp kbi sub inc incorporated reference form q quarterly report period ended june distribution agreement dated july astra merck enterprises inc astra pharmaceuticals lp incorporated reference form q quarterly report period ended june agreement incorporate defined terms dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp incorporated reference form q quarterly report period ended june computation ratios earnings fixed charges annual report stockholders portions incorporated reference document deemed filed code conduct values standards management contract compensatory plan arrangement table contents exhibit number description list subsidiaries consent independent accountants contained report power attorney certified resolution board directors rule ada certification chief executive officer rule ada certification chief financial officer section certification chief executive officer section certification chief financial officer none instruments defining rights holders longterm debt company subsidiaries exhibit number filed since total amount securities authorized instruments taken individually exceed total assets company subsidiaries consolidated basis company agrees furnish copy instruments commission upon request exhibit merck co inc deferral program amended restated november table contents article administration article ii eligibility article iii deferral deferred compensation account article iv valuation deferred compensation accounts article v redesignation within deferred compensation account article vi distribution deferred compensation accounts article vii deductions distributions article viii beneficiary designations article ix amendments schedule deferral program investment alternatives schedule ii special provisions applicable medco health employees imerck co inc deferral program deferral program program intended permit select group management defer income would otherwise immediately payable annual base salary various incentive plans merck co inc company administration program administered compensation benefits committee companys board directors committee composed nonemployee directors committee shall responsibility determining investments available program investments shall listed schedule hereto committee shall review investment selections least every five years committee shall make decisions affecting timing price amount deferred compensation participants subject section securities exchange act amended section officers may otherwise delegate authority program ii eligibility eligibility defer program determined accordance terms companys base salary deferral plan various incentive plans however committee authority refuse permit employee participate program committee determines participation would jeopardize programs compliance applicable law programs status top hat plan employee retirement income security act iii deferral deferred compensation account election defer participants decision defer program must made base salary deferral plan prior commencement pay period base salary deferred earned ii annual incentive plans prior commencement performance year bonus monies deferred earned iii longterm incentive plans prior commencement last year award period bonus monies deferred earned purposes annual incentive plans participant hired company performance year may make election later thirtieth th day participants date hire defer bonus monies earned performance year base salary deferral plan amounts equal excess five percent annual base salary defined base salary deferral plan less equal lesser fifty percent annual base salary participants annual base salary excess amount determined section internal revenue code may deferred annual longterm incentive plans amounts excess may deferred amounts deferred known deferred compensation credited participants deferred compensation account deferred compensation shall held one account regardless plan base salary deferral incentive plan deferred b election distribution schedule timing election participant shall also elect distribution schedule hisher deferred compensation participants election distribution schedule connection deferral election annual andor longterm incentive plans shall made time participant makes election defer participants initial election distribution schedule connection deferrals base salary deferral plan shall made time initial deferral election shall irrevocable calendar year made shall apply deferrals annual base salary new distribution election becomes effective thereafter election different distribution schedule connection deferrals base salary deferral plan may made time provided however new distribution schedule shall apply prospectively deferrals annual base salary following calendar year distribution schedule participant may elect payments begin participants actual retirement date subsequent date prior thereto participant may elect lump sum schedule annual installments maximum annual installments installment however may payable fifteen years participants termination employment c election investment alternatives participant shall designate accordance procedures established company designation portion multiples deferred compensation allocated investment alternative available program iv valuation deferred compensation accounts common stock initial crediting amount allocated merck common stock shall used determine number full partial shares merck common stock amount would purchase closing price merck common stock new york stock exchange date cash payments base salary amounts deferred base salary deferral plan incentive awards amounts deferred various incentive plans would otherwise paid participant deferral date committee determine valuation deferral date would constitute fair market value committee shall decide date fair market value shall determined using valuation method set forth paragraph company shall credit participants deferred compensation account number full partial shares merck common stock determined however time prior delivery shares shall shares purchased earmarked account participant shall rights shareholder respect shares credited hisher deferred compensation account dividends company shall credit participants deferred compensation account number full partial shares merck common stock purchasable closing price merck common stock new york stock exchange date dividend paid common stock dividends would paid number shares credited account including pro rata dividends partial share shares credited issued outstanding redesignations value merck common stock purposes redesignation shall closing price merck common stock new york stock exchange day redesignation request received pursuant administrative guidelines established human resources financial services area treasury department provided request received prior close new york stock exchange day ii next following business day request received new york stock exchange closed distributions distributions merck common stock valued closing price merck common stock new york stock exchange distribution date limitations shares merck common stock delivered provisions program may delivered company authorized unissued shares common stock common stock held treasury amount shares available year program shall one tenth onepercent outstanding shares merck common stock last business day preceding calendar year plus shares authorized program previous years used minus shares distributed executive incentive plan april adjustments event reorganization recapitalization stock split stock dividend combination shares merger consolidation rights offering change corporate structure shares company number kind shares merck common stock available program credited participants deferred compensation accounts shall adjusted accordingly b mutual funds initial crediting amount allocated mutual fund shall used determine number full partial mutual fund shares amount would purchase closing net asset value mutual fund shares deferral date company shall credit participants deferred compensation account number full partial mutual fund shares determined however mutual fund shares shall purchased earmarked account shall participant rights shareholder respect mutual fund shares dividends company shall credit participants deferred compensation account number full partial mutual fund shares purchasable closing net asset value mutual fund shares date dividend paid mutual fund shares dividends would paid number shares credited account including pro rata dividends partial share shares owned participant purposes computation redesignations value mutual fund shares purposes redesignation shall net asset value mutual fund close business day redesignation request received pursuant administrative guidelines established human resources financial services area treasury department provided request received prior close new york stock exchange day ii next following business day request received new york stock exchange closed distributions mutual fund distributions valued based closing net asset value mutual fund shares distribution date adjustments event reorganization recapitalization stock split stock dividend combination shares merger consolidation rights offering change corporate structure shares mutual fund number kind shares mutual fund credited participants deferred compensation accounts shall adjusted accordingly v redesignation within deferred compensation account basic redesignation rules participant beneficiary legal representative deceased participant may redesignate amounts credited deferred compensation account among investments available program accordance following rules eligible participants active employees separated employees retired participants eligible redesignate provided however redesignation shall made merck common stock frequency timing effective june limit number times participant may redesignate amounts measured mutual funds subject section b merck common stock redesignation shall take place day redesignation request received pursuant administrative guidelines established human resources financial services area treasury department provided request received prior close new york stock exchange day ii next following business day request received new york stock exchange closed amount extent redesignation redesignation must multiples investment redesignation made beneficiaries legal representatives beneficiary legal representative deceased participant may redesignate subject rules participants however beneficiary legal representative shall one opportunity redesignate amount merck common stock without regard rule set forth section b thereafter beneficiary legal representative shall subject redesignation rules participants including limitation redesignation merck common stock b special rules redesignation common stock eligible participants redesignation may made merck common stock unless participants balance merck common stock exceeds three times participants annual base salary purposes section b annual base salary active participant shall participants monthly base salary date redesignation requested retired participant monthly base salary date retirement annualized frequency timing section officers redesignations may made merck common stock window period established company timetotime amount redesignation amounts merck common stock restricted amounts excess three times annual base salary section officers redesignation amounts merck common stock also restricted amounts held merck common stock longer six months material nonpublic information committee sole discretion advice counsel time may rescind redesignation merck common stock redesignation made participant time redesignation possession material nonpublic information respect company b committees estimation benefited information timing hisher redesignation committees determination shall final binding event rescission participants deferred compensation account shall returned status though redesignation occurred notwithstanding committee shall rescind redesignation facts reviewed participant general counsel company designee prior redesignation general counsel designee concluded participant possession adverse material nonpublic information c conversion common stock accounts committee may sole discretion convert shares merck common stock allocated participants deferred compensation account manner provided position terminated retired participant taken wishes take opinion committee would make uncertain propriety participants continued interest merck common stock date conversion shall date commencement employment date committees action whichever later conversion shall expression value shares merck common stock participants deferred compensation account expression value united states dollars another available investment value merck common stock shall based upon closing price new york stock exchange date conversion trading took place day next business day trading took place conversion paragraph shall irrevocable absolute vi distribution deferred compensation accounts distribution deferred compensation accounts shall made accordance participants distribution schedule pro rata investment distributions merck common stock made shares cash payable partial share subject limitations set forth article iv section section officers distribution amounts merck common stock also restricted amounts held merck common stock longer six months distributions mutual funds cash distributions valued fifteenth day distribution month day business day next business day paid soon thereafter practicable retirement participants retirement active service cause distributions hisher deferred compensation account commence soon administratively feasible accordance participants previously elected schedule participant retires active service prior age committee may establish different distribution schedule schedule chosen committee however shall shorter participants previously elected schedule unless would significant change participants economic circumstances attributable participants early retirement committee decides change participants distribution schedule participants deferred compensation account must distributed ratably less five years however participant retired companys request limitation preceding sentence apply b death event participants death distributions program commence soon administratively feasible accordance hisher previously elected schedule participants beneficiary legal representative however may request committee change distribution schedule c automatic distribution participant terminates employment reasons death divestiture separation due reorganization reduction force elimination participants job take position joint venture business entity defined section e eligible retire active service one companys pension plans hisher deferred compensation account automatically paid lump sum soon administratively feasible following hisher termination employment furthermore except provided schedule ii participant dies retires active service whose employment terminates result divestiture separation due reorganization reduction force elimination participants job whose deferred compensation account valued less date hisher death retirement termination due divestiture separation hisher deferred compensation account distributed lump sum soon administratively feasible following hisher death retirement termination due divestiture separation termination due divestiture separation participant employed subsidiary company sold subsidiary longer considered within controlled group company participant shall considered terminated employment company purposes program participants employment terminates result divestiture division subsidiary company result separation due reorganization reduction force elimination participants job distributions program commence soon administratively feasible termination employment accordance hisher previously elected schedule schedule committee discretion may approve accordance section g e joint venture service participants termination employment order take position joint venture business entity company shall directly indirectly fifty percent outstanding voting ownership interest shall considered termination employment company purposes distribution program f hardship distributions committee sole discretion may accelerate time distribution participants deferred compensation account participant experiences severe financial hardship due illness accident death immediate family loss damage property due casualty extraordinary unforeseeable circumstances participant provide committee statement reasonable detail nature financial hardship together statement acceleration necessary alleviate hardship g postretirement postdivestiture postseparation modifications participant retired active service whose employment terminated result divestiture separation described section may submit one petition committee requesting extension period distribution hisher deferred compensation account petition must received committee prior first distribution participant hisher previously elected distribution schedule revised distribution schedule may exceed fifteen years date actual retirement divestiture separation date effective beginning next calendar year committee shall event grant new schedule participant would cumulatively receive greater portion hisher deferred compensation account measured end calendar year except provided schedule ii participant active employee may make request paragraph vii deductions distributions company deduct distribution amounts required withheld income social security tax purposes withholding done pro rata basis per investment company may also deduct amounts participant owes company reason viii beneficiary designations participant program may designate beneficiary receive hisher deferred compensation account upon participants death beneficiary predecease participant participant name beneficiary participants deferred compensation account distributed participants estate ix amendments committee may amend program time however amendment shall materially adversely affect right obligation respect deferred compensation made theretofore schedule deferral program investment alternatives january january merck common stock mutual funds american century emerging markets fund american funds europacific growth fund fidelity destiny fidelity dividend growth fidelity equityincome fund fidelity lowpriced stock fund fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income liberty acorn fundclass z pimco foreign bond institutional pimco long term us government institutional pimco total return institutional putnam global equity fund putnam international voyager putnam vista rowe price blue chip growth fund vanguard asset allocation september september investment briefly named putnam global growth fund result merger september putnam global equity fund putnam global growth fund merged fund briefly retained name putnam global growth fund effective october merged fund changed name putnam global equity fund schedule deferral program investment alternatives effective january july merck common stock mutual funds american century emerging markets institutional american funds europacific growth fund fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowpriced stock fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income liberty acorn class z pimco foreign bond institutional pimco long term us government institutional pimco total return institutional putnam global equity putnam international capital opportunities fund putnam vista rowe price blue chip growth vanguard asset allocation prior april known putnam international voyager fund redesignation deferred amounts measured putnam vista july prior pm et july participant part hisher deferred compensation account measured putnam vista investment alternative may redesignate amount investment alternative accordance article v section participant redesignate amount measured putnam vista investment alternative remaining investment alternatives pm et july amount putnam vista account shall redesignated pm et july fidelity midcap stock fund schedule deferral program investment alternatives effective july november merck common stock mutual funds american century emerging markets institutional american funds europacific growth fund columbia acorn fund z fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowpriced stock fidelity midcap stock fund fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income pimco foreign bond institutional pimco long term us government institutional pimco total return institutional putnam global equity putnam international capital opportunities fund rowe price blue chip growth vanguard asset allocation prior october known liberty acorn class z prior april known putnam international voyager fund redesignation deferred amounts measured putnam global equity putnam international capital opportunities fund collectively putnam funds november prior pm et november participant part hisher deferred compensation account measured putnam funds investment alternative may redesignate amount investment alternative accordance article v section participant redesignate amount measured putnam funds investment alternative remaining investment alternatives pm et november amount putnam funds investment alternative shall redesignated pm et november fidelity retirement money market portfolio schedule deferral program investment alternatives effective november merck common stock mutual funds american century emerging markets institutional american funds europacific growth fund columbia acorn fund z fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowpriced stock fidelity midcap stock fund fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income liberty acorn class z pimco foreign bond institutional pimco long term us government institutional pimco total return institutional rowe price blue chip growth vanguard asset allocation prior october known liberty acorn class z schedule ii special provisions applicable medco health employees approved july definitions medco health medco health solutions inc medco health employee participant employed medco health prior spinoff ii employed merck prior spinoff expected employed medco health prior spinoff separated medco health employee participant deferral program employed medco health date spinoff considered terminated employment company result spinoff spinoff distribution merck shareholders equity securities medco health spinoff divestiture purposes deferral program special provisions notwithstanding anything contrary article vi section c deferral program deferred compensation account separated medco health employee shall paid accordance article vi section without regard threshold set forth section c notwithstanding anything contrary article vi section g deferral program medco health employee may submit petition extension distribution schedule permitted section g either prior spinoff medco health employee become separated medco health employee provided however medco health employee makes request new distribution schedule prior spinoff thereafter become separated medco health employee request shall effective exhibit merck co inc plan deferred payment directors compensation amended restated november table contents article purpose article ii election deferral measurement methods distribution schedule article iii valuation deferred amounts article iv redesignation within deferral account article v payment deferred amounts article vi designation beneficiary article vii plan amendment termination schedule measurement methods imerck co inc plan deferred payment directors compensation purpose provide arrangement directors merck co inc current employees may elect voluntarily defer payment annual retainer meeting committee fees termination service director ii value compensation mandatorily deferred behalf ii election deferral measurement methods distribution schedule election voluntary deferral amount prior december year director entitled make irrevocable election defer termination service director receipt payment retainer months beginning april next calendar year b committee chairperson retainer beginning april next calendar year c meeting committee fees months beginning april next calendar year prior commencement duties director director newly elected appointed board calendar year must make election paragraph portion voluntary deferral amount applicable directors first year service part thereof voluntary deferral amount shall credited follows meeting committee fees deferred credited day directors services rendered board retainer andor committee chairperson retainer deferred prorata share deferred retainer credited last business day calendar quarter dates voluntary deferral amount parts thereof credited directors deferred account hereinafter referred voluntary deferral dates b mandatory deferral amount friday following companys annual meeting stockholders friday hereinafter referred mandatory deferral date director credited amount equivalent onethird annual cash retainer month period beginning april preceding annual meeting mandatory deferral amount mandatory deferral amount measured merck common stock account director newly elected appointed board mandatory deferral date credited pro rata portion mandatory deferral amount applicable directors first year service part thereof pro rata portion shall credited directors account first day directors service c election measurement method annual election referred section shall include election measurement method methods value amounts deferred measured accordance article iii available measurement methods set forth schedule hereto election distribution schedule annual election referred section shall also include election receive payment following termination service director voluntary deferral amounts mandatory deferral amounts lump sum either immediately one year termination quarterly annual installments five ten fifteen years iii valuation deferred amounts common stock initial crediting annual mandatory deferral amount shall used determine number full partial shares merck common stock amount would purchase closing price common stock new york stock exchange mandatory deferral date portion voluntary deferral amount allocated merck common stock shall used determine number full partial shares merck common stock amount would purchase closing price common stock new york stock exchange applicable voluntary deferral date however determined committee corporate governance board directors measurement merck common stock mandatory voluntary deferral date would constitute fair market value committee shall decide date fair market value shall determined using valuation method set forth article iii section time deferral period shares merck common stock purchased earmarked deferred amounts rights shareholder exist respect amounts dividends directors account credited additional number full partial shares merck common stock would purchasable dividends shares previously credited account closing price common stock new york stock exchange date dividend paid distributions distribution merck common stock account valued closing price merck common stock new york stock exchange distribution date b mutual funds initial crediting amount allocated mutual fund shall used determine full partial mutual fund shares amount would purchase closing net asset value mutual fund shares mandatory voluntary deferral date whichever applicable directors account credited number full partial mutual fund shares determined time deferral period mutual fund shares purchased earmarked deferred amounts rights shareholder exist respect amounts dividends directors account credited additional number full partial mutual fund shares would purchasable closing net asset value mutual fund shares date dividend paid mutual fund shares dividends would paid number shares previously credited account including pro rata dividends partial shares distributions mutual fund distributions valued based closing net asset value mutual fund shares distribution date c adjustments event reorganization recapitalization stock split stock dividend combination shares merger consolidation rights offering change corporate structure shares company mutual fund number kind shares units investment measurement method available plan credited directors account shall adjusted accordingly iv redesignation within deferral account general director may request change measurement methods used value portion hisher account merck common stock amounts deferred using merck common stock method earnings attributable deferrals may redesignated change effective day redesignation request received pursuant administrative guidelines established human resources financial services area treasury department provided request received prior close new york stock exchange day ii next following business day request received new york stock exchange closed b redesignation may occur active service limit number times director may redesignate portion hisher deferred account permitted redesignated request shall irrevocable designated whole percentages dollar amount death following death director legal representative beneficiary director may redesignate subject rules active directors set forth article iv section b c valuation amounts redesignated portion directors account redesignated valued cash equivalent cash equivalent converted shares units measurement methods purposes redesignations cash equivalent value mutual fund shares shall closing net asset value mutual fund day redesignation request received pursuant administrative guidelines established human resources financial services area treasury department provided request received prior close new york stock exchange day ii next following business day request received new york stock exchange closed v payment deferred amounts payment payments directors amounts deferred cash accordance distribution schedule elected director pursuant article ii section distributions shall pro rata measurement method distributions shall valued fifteenth day distribution month day business day next business day paid soon thereafter possible b changes distribution schedule prior termination upon request director made time calendar year immediately preceding calendar year service director expected terminate committee corporate governance board directors committee sole discretion may authorize extension payment period beyond originally elected director exceed otherwise allowable article ii section andor b payment frequency different originally elected director request may made regard amounts deferred december using merck common stock method earnings attributable deferrals deferrals merck common stock made december earnings thereon may distributed accordance schedule elected director article ii section determined committee corporate governance article vi c posttermination changes distribution schedule following termination service director director may make one request extension period distribution hisher deferred compensation request must received committee corporate governance prior first distribution participant hisher previously elected distribution schedule revised distribution schedule may exceed deferral period otherwise allowable article ii section c request may granted new payment schedule determined sole discretion committee corporate governance request may made regard amounts deferred december using merck common stock method earnings attributable deferrals retired director subject us income tax may petition committee corporate governance change payment frequency including lump sum distribution committee corporate governance may grant petition discretion considers reasonable justification therefor deferrals merck common stock made december earnings thereon may distributed accordance schedule elected director article ii section determined committee corporate governance article vi forfeitures directors deferred amount attributable mandatory deferral amount earnings thereon shall forfeited upon removal director upon determination committee corporate governance sole discretion director joined board managed operated participated material way entered employment performed consulting services otherwise connected material manner company corporation enterprise firm limited partnership partnership person sole proprietorship business entity determined committee corporate governance sole discretion competitive business company subsidiaries affiliates competitor ii directly indirectly acquired equity interest five percent greater competitor iii disclosed material trade secrets material confidential information including customer lists relating company business company others including competitor vi designation beneficiary event death director deferred amount date death shall paid last named beneficiary beneficiaries designated director beneficiary designated directors legal representative one installments committee corporate governance sole discretion may determine vii plan amendment termination committee corporate governance shall right amend terminate plan time reason schedule measurement methods january january merck common stock mutual funds american century emerging markets fund american century europacific growth fund fidelity destiny fidelity dividend growth fidelity equity income fund fidelity lowpriced stock fund fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income liberty acorn z pimco foreign bond institutional pimco long term us government institutional pimco total return institutional putnam global equity fund putnam international voyager putnam vista rowe price blue chip growth fund vanguard asset allocation september september investment briefly named putnam global growth fund result merger september putnam global equity fund putnam global growth fund merged fund briefly retained name putnam global growth fund effective october merged fund changed name putnam global equity fund schedule measurement methods effective january july merck common stock mutual funds american century emerging markets institutional american funds europacific growth fund fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowpriced stock fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income liberty acorn class z pimco foreign bond institutional pimco long term us government institutional pimco total return institutional putnam global equity putnam international capital opportunities fund putnam vista rowe price blue chip growth vanguard asset allocation prior april known putnam international voyager fund redesignation deferred amounts measured putnam vista july prior pm et july participant part hisher account measured putnam vista measurement method may redesignate amount measurement method accordance article iv participant redesignate amount measured putnam vista measurement method remaining measurement method pm et july amount putnam vista account shall redesignated pm et july fidelity midcap stock fund schedule measurement methods effective july november merck common stock mutual funds american century emerging markets institutional american funds europacific growth fund columbia acorn class z fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowpriced stock fidelity midcap stock fund fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income pimco foreign bond institutional pimco long term us government institutional pimco total return institutional putnam global equity putnam international capital opportunities fund rowe price blue chip growth vanguard asset allocation prior october known liberty acorn class z prior april known putnam international voyager fund redesignation deferred amounts measured putnam global equity putnam international capital opportunities fund collectively putnam funds november prior pm et november participant part hisher deferred compensation account measured putnam funds investment alternative may redesignate amount investment alternative accordance article iv participant redesignate amount measured putnam funds investment alternative remaining investment alternatives pm et november amount putnam funds investment alternative shall redesignated pm et november fidelity retirement money market portfolio schedule measurement methods effective november merck common stock mutual funds american century emerging markets institutional american funds europacific growth columbia acorn class z fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowpriced stock fidelity midcap stock fund fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income pimco foreign bond institutional pimco long term us government institutional pimco total return institutional rowe price blue chip growth vanguard asset allocation prior october known liberty acorn class z exhibit december dr peter kim baskin road lexington dear peter pleasure offer position executive vice president research development merck research laboratories grade merck co inc merck company gross base salary per month subject appropriate tax payroll withholding deductions effective february position primary work location west point pa merck research laboratories salaried employees currently paid monthly basis specific details offer include following soon practicable commencing employment merck february receive onetime signon bonus net income taxes required paid voluntarily terminate employment merck ie resign within months start date required reimburse company prorated portion bonus eligible consideration merck co inc incentive stock plan stock option purchase merck stock approximate market price date option granted subject terms specific option grant option holders may purchase stock vesting period currently five years original option price number shares granted determined year company assuming begin employment february granted nonqualified stock option grant shares merck stock company makes annual stock option grants begin employment february grant issued next quarterly stock option grant date falls calendar quarter following date hire except described paragraph option granted terms conditions including vesting terms apply generally annual grants made applicable year grade employees however option granted prior may vest immediately upon termination company employment company prior may reason gross misconduct ii termination employment company prior usual vesting date grant company either fails appoint may succeed dr edward scolnick president mrl b appoints may someone president mrl option special vesting terms vests result either ii five years accelerated vesting date option exercise option addition company terminates employment reason grossmisconduct period effective date raymond v gilmartins retirement second anniversary retirement options granted prior termination date vested termination date shall vest immediately termination date exercisable five years thereafter purposes letter gross misconduct means unauthorized disclosure information known proprietary confidential embezzlement theft misappropriation merck assets falsification records reports deliberate reckless action causes actual potential injury loss company employees company failure carry assigned duties notice writing failure corrected result termination employment illegal act company property representing company eligible annual consideration receive cash bonus companys executive incentive plan eip grade hire opportunity within first calendar days employment elect defer part cash bonus may receive performance year day period represents opportunity elect deferral option performance year opportunity limited new hires grades subject us taxes performance year january december bonuses paid following march bonus performance year less gross subject appropriate tax payroll withholding deductions assuming begin employment february future increases salary continued participation executive incentive plan based annual performance administered performance management plan accordance companys compensation policies eligible participate exceptional flexible benefits program includes following plans medical dental life insurance accidental death dismemberment insurance survivors income benefits dependent life insurance longterm disability insurance longterm care insurance financial planning program two tax free accounts health care reimbursement dependent care reimbursement please feel free contact steve g sheehan vice president mrlisww licensing human resources directly need details benefit programs additionally eligible participate employee savings security plan taxdeferred k plan companypaid pension plan presently taxqualified plan may roll eligible distribution plan k plan taxdeferred k plan managed fidelity investments includes wide variety investment options eligible days vacation annually accordance company policy accrued monthly basis upon written acceptance offer defray reasonable relocation expenses amount less incurred consists limited costs fees including professional fees incurred negotiating agreement terminating employment howard hughes medical institute disposing residence massachusetts moving personal household effects permanent residence new location currently home intend purchase new location please contact realtor receive list authorized brokers relocationdepartment relocation consultant contact directly review relocation benefits make proper arrangements questions specifically regarding relocation benefits prior consultant contacting please call barbara turansky merck co inc west point pennsylvania please note arrangements carrier must handled directly merck relocation allowances subject us federal income tax accordance federal statutes home assistance program amount based need approved provided directly one three merck authorized mortgage companies behalf addition funds payment home assistance program applied offset mortgage balance program considered second mortgage resulting lien placed property close simultaneously first mortgage lien subsequent taxes due funds cover period five years appropriate taxes deducted monthly payroll leave merck lien taxes satisfied would obligated repay prorated portion original home assistance program complete details program including list mortgage companies provided relocation counselor please advised offer contingent upon following successfully completing drug screen evaluation proof eligibility work united states contingencies met confirm offer february starting date employment merck subject mercks terms conditions employment provided offer confirmed advise altering current employment status contingencies met order schedule preplacement health evaluation drug screen please contact dr robert falcone corporate medical director employee health services merck co inc whitehouse new jersey great deal confidence extend offer impressed achievements strong motivation successful scientific career believe possess qualities would complement contribute attainment research goals certain merck provide environment stimulating rewarding expectation merck succeed dr edward scolnick president mrl succeed dr edward scolnick president mrl may choose return academia employee merck employee means either merck may terminate employment relationship time lawful reason order accommodate concern returning academia merck agrees may appointed merck succeed dr edward scolnick president mrl may someone appointed merck succeed dr scolnick president mrl prior second anniversary effective date raymond v gilmartins retirement employment terminated merck reason gross misconduct merck shall give onetime grant academic institution designated sole purpose enabling set maintain research laboratory employee institution provided designated institution hires employee later one year first contingencies occurs since purpose grant provide significant benefit condition precedent mercks implementation special arrangement upon termination merck employment must sign comply noncompete nondisclosure provisions waiver release claims format prescribed merck provided terms provisions applicable shall less favorable terms prescribed merck departing mrl employee grade preceding five years favorable departing employee look forward receiving favorable response writing sincerely hope find merck co inc career opportunities seeking would appreciate receiving written reply soon possible later december nd answer questions provide assistance way please hesitate contact sincerely edward scolnick note benefits bonuses stock options provided granted subject terms applicable plan documents plans may amended time time company copy susan paulosky steve g sheehan ginny stephens kenneth j weiss wendy l yarno new employee administrationexhibit merck co inc subsidiaries computation ratios earnings fixed charges millions except ratio data years ended december income continuing operations taxes add subtract onethird rents interest expense gross interest capitalized net amortization equity income loss affiliates net distributions preferred stock dividends net tax earnings continuing operations onethird rents interest expense gross preferred stock dividends fixed charges continuing operations ratio earnings fixed charges continuing operations purposes computing ratios earnings consist income taxes onethird rents deemed company representative interest factor inherent rents interest expense net amounts capitalized equity income loss affiliates net distributions dividends preferred stock subsidiary companies fixed charges consist onethird rents interest expense reported companys consolidated financial statements dividends preferred stock subsidiary companiesexhibit financial section contents financial review description mercks business overview competition health care environment operating results selected joint venture affiliate information capital expenditures analysis liquidity capital resources critical accounting policies matters recently issued accounting standards cautionary factors may affect future results cash dividends paid per common share common stock market prices condensed interim financial data consolidated statement income consolidated statement retained earnings consolidated statement comprehensive income consolidated balance sheet consolidated statement cash flows notes consolidated financial statements managements report report independent auditors audit committees report compensation benefits committees report selected financial data financial review description mercks business merck global researchdriven pharmaceutical products company discovers develops manufactures markets broad range innovative products improve human animal health directly joint ventures merck sells products primarily drug wholesalers retailers hospitals clinics government agencies managed health care providers health maintenance organizations institutions companys professional representatives communicate effectiveness safety value products health care professionals private practice group practices managed care organizations august merck completed spinoff medco health solutions inc medco health following spinoff companys prior period consolidated statements income cash flows related discussions restated present results medco health separately discontinued operations result spinoff product sales reflect sales medco health thirdparty sales based upon net selling price merck medco health prior year amounts restated conform current year presentation overview merck remains committed strategy discovering developing novel medicines vaccines confident ability drive longterm shareholder value company withdrew two products latephase clinical trials despite setbacks mercks research development efforts continue foundation company continuing focus developing launching novel medicines vaccines backed proven outcomes competitive prices aggressively pursuing external alliances lowering companys cost structure maximizing inline franchises allow merck grow succeed long term company completed successful spinoff medco health increased ownership banyu pharmaceutical co ltd banyu one japans top pharmaceutical companies two actions make merck focused pharmaceutical research company stronger position japan worlds secondlargest market november us food drug administration fda accepted filing new drug application nda merckscheringplough pharmaceuticals partnership merck scheringplough corporation scheringplough vytorin contains active ingredients zetia ezetimibe zocor simvastatin investigational cholesterollowering medicine developed reduction elevated cholesterol levels hypercholesterolemia december merck resubmitted expanded nda fda arcoxia newest coxib treatment osteoarthritis rheumatoid arthritis chronic low back pain acute pain dysmenorrhea acute gouty arthritis ankylosing spondylitis merck co inc annual report addition submissions merck novel vaccine candidates diabetes drug drug sleep disorders latestage pipeline companys preclinical phase ii programs span significant number therapeutic categories include work areas diabetes obesity alzheimers disease respiratory disease coronary heart disease rheumatoid arthritis vaccines new technologies give merck potential move compound candidates later stages development faster merck supplements internal research aggressive licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds company accelerated efforts fundamentally lower cost structure companywide initiatives october merck announced reduction positions expected completed addition fourth quarter company implemented new distribution program us wholesalers moderate fluctuations sales caused wholesaler investment buying improve efficiencies distribution merck pharmaceutical products mercks major inline franchises ranks either class worldwide sales success driven largely mercks focus developing novel medicines demonstrating value proven health outcomes mercks strong financial profile enables company fully fund research development aggressively focus external alliances support inline products maximize upcoming launches providing significant cash returns shareholders earnings per common share assuming dilution continuing operations including impact implementation new distribution program us wholesalers restructuring costs related position eliminations continuing operations excluded results medco health company anticipates fullyear earnings per common share assuming dilution including effect restructuring costs competition health care environment markets company conducts business highly competitive often highly regulated global efforts toward health care cost containment continue exert pressure product pricing access united states government made significant progress expanding health care access adding prescription drug coverage medicare beginning implementing voluntary drug discount card medicare beneficiaries effective june implementation new benefit support companys goal improving access medicines expanding insurance coverage preserving marketbased incentives pharmaceutical innovation time benefit designed assure prescription drug costs controlled competitive pressures encouraging appropriate use medicines company taken leadership role contributing success new medicareendorsed discount cards providing medicines free lowincome medicare beneficiaries exhaust transitional assistance allowance medicareendorsed drug discount cards action consistent companys longstanding patient assistance program provides free medicines patients united states lack drug coverage afford medicines addressing cost containment outside medicare company made continuing effort demonstrate medicines help save costs overall patient health care addition pricing flexibility across companys product portfolio encouraged growing use medicines mitigated effects increasing cost pressures outside united states difficult environments encumbered government cost containment actions company worked partnership payers allocating scarce resources optimize health care outcomes limiting potentially detrimental effects government policies sales growth supporting discovery development innovative products benefit patients company also working governments many emerging markets latin america asia encourage increase investments health thereby improve citizens access medicines countries within european union eu recognizing economic importance researchbased pharmaceutical industry value innovative medicines society working industry representatives european commission proposals complete single market pharmaceuticals improve competitive climate variety means including market deregulation company committed improving access medicines enhancing quality life people around world mercks african comprehensive hivaids partnerships achap botswana collaboration government botswana bill melinda gates foundation striving develop comprehensive sustainable approach hiv prevention care treatment catalyze access hiv medicines developing countries october company began introduce new mg tablet formulation antiretroviral medicine stocrin price less one dollar per day least developed countries hardest hit hivaids epidemic end patients developing countries treated antiretroviral regimens containing either crixivan stocrin actions merck working partners public private sectors alike focus real barriers access medicines developing world need sustainable financing increased international assistance additional investments education training health infrastructure capacity developing countries increasing amount focus privacy issues countries around world including united states eu united states federal state governments pursued legislative regulatory initiatives regarding patient privacy including recently issued federal privacy regulations concerning health information affected companys operations although one predict outcome legislative regulatory advocacy initiatives company wellpositioned respond evolving health care environment market forces company anticipates worldwide trend toward cost containment continue resulting ongoing pressures health care budgets company continues successfully launch new products contribute health care debates monitor reforms new products policies strategies enable maintain strong position changing economic environmentmerck co inc annual report operating results sales worldwide sales increased total reflecting favorable effect foreign exchange favorable effect price changes overall increase reflects strong growth singulair asthma seasonal allergic rhinitis fosamax osteoporosis cozaar hyzaar high blood pressure also contributing increase sales vioxx arcoxia arthritis pain cancidas infections cosopt glaucoma proscar benign prostate enlargement maxalt migraines revenues companys relationship astrazeneca lp azlp also added overall growth domestic sales increased foreign sales grew sales united states unfavorably impacted implementation new distribution program us wholesalers described foreign sales negatively affected loss basic patent protection zocor modifying cholesterol canada certain countries europe including united kingdom germany foreign sales represented total sales historically anticipation possible price increases certain us wholesalers placed noncancellable orders prices remained effect merck shipped product fourth quarter company implemented new distribution program us wholesalers moderate fluctuations sales caused wholesaler investment buying improve efficiencies distribution merck pharmaceutical products new program lowered previous limits average monthly purchases merck pharmaceutical products us customers overall implementation new us wholesaler distribution program estimated million unfavorable impact consolidated revenues estimated million unfavorable effect zocor sales worldwide sales increased total volume basis foreign exchange less onehalf point unfavorable effect sales growth price changes essentially effect growth foreign sales represented total sales sales category companys products follows millions atherosclerosis hypertensionheart failure antiinflammatoryanalgesics osteoporosis respiratory vaccinesbiologicals antibacterialantifungal ophthalmologicals urology human immunodeficiency virus hiv presented net rebates discounts companys products include therapeutic preventive agents generally sold prescription treatment human disorders among atherosclerosis products zocor largestselling hypertensionheart failure products significant cozaar hyzaar vasotec antiinflammatoryanalgesics include vioxx arcoxia agents specifically inhibit cox enzyme responsible pain inflammation coxibs osteoporosis product fosamax treatment prevention osteoporosis respiratory product singulair leukotriene receptor antagonist treatment asthma relief symptoms seasonal allergic rhinitis vaccinesbiologicals mmr ii pediatric vaccine measles mumps rubella varivax live virus vaccine prevention chickenpox recombivax hb hepatitis b vaccine recombinant largestselling antibacterialantifungal products includes primaxin well newer products cancidas invanz ophthalmologicals cosopt trusopt largestselling urology product proscar treatment symptomatic benign prostate enlargement hiv products include crixivan stocrin treatment human immunodeficiency viral infection adults primarily includes sales human pharmaceuticals pharmaceutical animal health supply sales companys joint ventures revenue companys relationship azlp primarily relating sales nexium prilosec revenue azlp billion billion billion respectively zocor mercks statin modifying cholesterol achieved worldwide sales billion decline implementation new us wholesaler distribution program unfavorably impacted zocor sales approximately million year sales zocor also affected increased competition statin market loss basic patent protection canada certain countries europe including united kingdom germany patent expirations unfavorable impact sales comparison us mailorder adjusted prescription levels zocor increased approximately april fda approved new indication zocor based results landmark heart protection study hps demonstrated thatalong diet zocor mg first cholesterollowering medication proven save lives reducing risk heart attack stroke people heart disease diabetes regardless cholesterol level results subgroup analysis hps published june issue lancet showed treatment zocor mg lowered incidence heart attacks stroke people diabetes regardless cholesterol glucose levels merck continues communicate results landmark hps physicians consumers merck co inc annual report may new contract took effect whereby zocor selected sole highpotency hmg agent statin us department veteran affairs department defense high potency defined contract lowering ldlc least zocor lose market exclusivity united states company expects decline us sales fosamax prescribed medicine worldwide treatment postmenopausal male glucocorticoidinduced osteoporosis continued strong growth sales billion increase us mailorderadjusted prescription levels fosamax increased approximately fosamax weekly launched markets worldwide potential continued growth osteoporosis market remains strong fewer women osteoporosis seven major markets diagnosed treated april international study published archives internal medicine showing women stopped hormone replacement therapy hrt experienced significant bone loss year following discontinuation study also showed fosamax prevented bone loss many women helped increase bone density spine maintained bone density hip postmenopausal women stopped hrt june published study versus actonel administered approved oncedaily dosing regimen europe study conducted fosamax mg weekly provided significantly greater increases bone mineral density spine hip similar tolerability september results two headtohead studies presented annual meeting american society bone mineral research studies efficacy fosamax vs evista comparison trial effect demonstrated superiority fosamax versus evista raloxifene treatment postmenopausal osteoporosis fosamax mg weekly providing significantly greater increases bone mineral density spine hip raloxifene mg daily global sales cozaar companion agent hyzaar combination cozaar diuretic hydrochlorothiazide treatment hypertension strong reaching billion increase us mailorderadjusted prescription levels cozaar hyzaar increased approximately cozaar hyzaar compete fastestgrowing class antihypertensive market cozaar secondmostfrequently prescribed angiotensin ii antagonist aiia united states largestselling aiia europe march fda approved cozaar first aiia indicated reduce risk stroke patients hypertension left ventricular hypertrophy lvh new indication based landmark losartan intervention endpoint reduction hypertension life study life study demonstrated treatment regimen based cozaar reduced risk stroke patients hypertension lvh versus treatment regimen based beta blocker atenolol study black patients hypertension lvh lower risk stroke atenolol cozaar two separate sets hypertension guidelines issued seventh report joint national committee prevention detection treatment high blood pressure united states may european society hypertensioneuropean society cardiology guidelines europe june support use aiias treatment certain groups patients based part landmark life reduction endpoints non insulin dependent diabetes mellitus angiotensin ii antagonist losartan renaal studies cozaar renaal study patients hypertension type ii diabetes nephropathy cozaar significantly delayed doubling serum creatinine marker kidney disease significantly delayed progression endstage renal disease esrd condition requiring dialysis renal transplantation survival effect overall mortality cozaar medicine demonstrated significant reduction risk esrd patients type ii diabetes nephropathy hypertension thirtytwo countries granted new regulatory licenses cozaar based life study countries done based renaal merck ei du pont de nemours company dupont began sharing equally operating profits cozaar hyzaar north america terms license agreement established parties financial terms outside north america changed worldwide sales vioxx mercks first onceaday coxib grew achieving billion sales although us mailorder adjusted prescription levels vioxx decreased approximately vioxx remains widely available coxib managed care formularies united states vioxx coxib united states offers hour pain relief oncedaily tablet indications million prescriptions written united states since introduction outside united states vioxx bestselling arthritis pain medicine data presented th annual scientific meeting american academy neurology april profiled research results vioxx treatment acute migraine headaches vioxx mg daily mg daily relieved acute migraine pain within two hours reduced certain symptoms associated migraine headaches moderate severe intensity vioxx welltolerated compared placebo patient study supplemental ndas review fda additional indications acute migraine juvenile rheumatoid arthritis approved uses expected enhance efficacy profile vioxx arcoxia mercks newest coxib continues launched countries outside united states december arcoxia launched countries europe latin america asia worldwide sales reaching million year merck co inc annual report december company submitted nda arcoxia fda seeking indications treatment osteoarthritis rheumatoid arthritis chronic low back pain acute pain dysmenorrhea acute gouty arthritis ankylosing spondylitis painful condition spine fda determine whether accept mercks application submitted june new studies presented annual congress european league rheumatism showed arcoxia provided sustained pain relief patients osteoarthritis rheumatoid arthritis treatment effects maintained duration studymore three years osteoarthritis study one year rheumatoid arthritis studies results investigational study arcoxia patients chronic low back pain published august issue journal pain study showed arcoxia mg mg daily provided significant improvement relief symptoms disability associated chronic low back pain compared placebo improvement observed one week initiating therapy maximum relief observed four weeks relief maintained throughout threemonth study november european unions committee proprietary medicinal products concluded comprehensive review cox selective inhibitor class includes vioxx arcoxia confirmed medicines positive balance benefits risks singulair mercks onceaday oral medication indicated treatment chronic asthma relief symptoms seasonal allergic rhinitis hay fever continued strong performance singulair secondmostprescribed product overall respiratory market united states total sales singulair billion increase us mailorderadjusted prescription levels singulair increased approximately first quarter merck launched new indication singulair relief symptoms seasonal allergic rhinitis adults children young years age singulair represents novel way treat seasonal allergies blocks leukotrienes instead histamine may offer relief many million people united states suffer form allergic rhinitis twentyeight countries outside united states also approved new indication september merck announced made singulair available united states prevention treatment chronic asthma children ages months years new convenient onceaday oral granules formulation new formulation represents first nonsteroidal oncedaily oral asthma controller medication approved children young months oral granules formulation singulair also used relief symptoms seasonal allergies children ages years asthma common chronic childhood illness affecting million children united states alone increasing prevalence children years also september merck presented results new study prevention virally induced asthma previa th annual congress european respiratory society previa showed young children whose asthma triggered colds experienced significantly fewer asthma attacks treated singulair compared placebo viruses cause common cold respiratory infections account childhood asthma attacks march fda approved emend first member new class medicines help prevent acute delayed nausea vomiting associated highly emetogenic cancer chemotherapy presentations th annual meeting american society clinical oncology demonstrated treatment regimen containing emend reduced impact chemotherapyinduced nausea vomiting patients daily functioning sales growth also benefited cancidas first new class antifungals called echinocandins glucan synthesis inhibitors introduced decade cancidas used treat certain lifethreatening fungal infections becoming prevalent number people compromised immune systems increases medicine indicated treatment candidemia bloodstream infection following candida infections intraabdominal abscesses peritonitis infections within lining abdominal cavity pleural space infections infections within lining lung also indicated esophageal candidiasis invasive aspergillosis patients respond tolerate antifungal therapies amphotericin b lipid formulations amphotericin b andor itraconazole products experiencing growth included antibiotic primaxin proscar treatment symptomatic benign prostate enlargement maxalt treatment acute migraine headaches adults cosopt treat glaucoma propecia male pattern hair loss invanz treatment selected moderate severe infection adults crixivan though still contributing sales declined unit volume result therapeutic competition also contributing mercks total sales revenue resulting companys relationship azlp primarily relating sales nexium global sales zetia cholesterol absorption inhibitor developed marketed merckscheringplough pharmaceuticals reached million million prescriptions written united states since us launch zetia midnovember according ims health zetia currently accounts new prescriptions us cholesterolmodifying market zetia reimbursed nearly patients managed care plans united states company records interest merckscheringplough partnerships equity income affiliates zetia first new class come market cholesterol management category since statins introduced years ago works lower cholesterol unique way inhibiting cholesterol absorption intestine zetia often combined statins work inhibiting cholesterol synthesis liver following successful completion european union mutual recognition procedure ezetrol brand name zetia outside united states launched five european countriesgermany united kingdom switzerland sweden netherlandsmerck co inc annual report september merckscheringplough pharmaceuticals submitted nda fda vytorin contains active ingredients zetia ezetimibe zocor simvastatin approved product would first single medication target bodys two sources cholesterol dual inhibitioninhibiting cholesterol production liver absorption intestine november filing accepted fda standard review similar applications filed countries outside united states costs expenses millions change change materials production marketing administrative research development acquired research equity income affiliates income expense net greater materials production materials production costs increased compared sales growth rate excluding effects exchange inflation costs increased compared sales volume level increase costs relative sales volume reflects effect changes product mix well change mix domestic foreign sales attributable part implementation new distribution program us wholesalers materials production costs increased compared sales growth rate primarily attributable effect changes product mix excluding effects exchange inflation costs increased eight points higher unit sales volume growth gross margin compared marketing administrative marketing administrative expenses increased excluding effects exchange inflation costs increased primarily attributable impact million restructuring costs related position eliminations company accelerated efforts fundamentally lower cost structure companywide initiatives october company announced reduction positions expected completed approximately positions eliminated december additional restructuring costs expected incurred complete cost reductions expected generate annual savings payroll benefits costs million starting company continues seek opportunities improve business processes reduce cost structure marketing administrative expenses decreased total volume basis marketing administrative expenses percentage sales research development research development expenses increased excluding effects exchange inflation expenses increased research development expense growth reflects companys ongoing commitment basic clinical research well new research collaborations mercks latestage pipeline candidates include novel vaccines human papillomavirus hpv pain associated shingles rotateq vaccine rotavirus highly contagious virus common cause severe gastroenteritis infants young children merck expects file product license applications plas fda three novel vaccine candidates second half competing claims intellectual property hpv field company confident claims delay companys program company expects submit pla fda proquad vaccine pediatric combination vaccine measles mumps rubella chickenpox second half company also studying dpiv inhibitor glucoselowering mechanism used alone combination treatment type ii diabetes merck plans enter phase iii clinical trials investigational compound second quarter expects submit nda fda mercks earlystage pipeline includes candidates following areas diabetes obesity alzheimers disease respiratory disease coronary heart disease rheumatoid arthritis vaccines company supplements internal research aggressive licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies merck completed significant transactions including research collaborations preclinical clinical compounds technology transactions compared transactions completed include agreements following companies genpath cancer amrad respiratory disease neurogen pain actelion cardiovascular disease february company announced entered agreement h lundbeck lundbeck develop commercializein united states gaboxadol compound licensed lundbeck third party currently phase iii development treatment sleep disorders terms agreement lundbeck receive initial payment million million additional milestone payments company lundbeck jointly complete ongoing phase iii clinical program company funding majority remaining development activities company anticipates file nda fda late mid following fda approval companies plan copromote gaboxadol united states lundbeck receive share gaboxadol sales united states february company announced agreed acquire aton pharma inc aton privately held biotechnology company focusing development novel treatments cancer serious diseases consideration acquisition consist upfront contingent payments based upon regulatory filing approval sales products atons clinical pipeline histone deacetylase inhibitors represents class antitumor agents potential efficacy based novel mechanism action atons lead product candidate known suberoylanilide hydroxamic acid extensively studied phase clinical trials currently phase ii clinical trials treatment cutaneous tcell lymphoma company expects complete acquisition aton first quarter merck co inc annual report chart reflects companys research pipeline march candidates shown phase iii include specific products candidates shown phase ii include advanced compound specific mechanism given therapeutic area backup compounds regardless phase development additional indications therapeutic areas additional line extensions formulations inline products shown preclinical areas shown company initiated good laboratory practices glp studies compounds mechanisms distinct phase ii companys programs generally designed focus development novel medicines address large unmet medical needs research pipeline preclinical diabetes atherosclerosis parkinsons disease pain anxiety osteoporosis cancer rheumatoid arthritis glaucoma antibacterial vaccines phase diabetes c obesity c c atherosclerosis c alzheimers disease c c multiple sclerosis c pain c psychiatric disease c respiratory disease c rheumatoid arthritis c c aids c vaccines hiv vaccine phase ii obesity c alzheimers disease c urinary incontinence c respiratory disease c postoperative nausea vomiting c vaccines pediatric combination phase iii pediatric combination vaccine proquad rotavirus vaccine rotateq shingles zoster vaccine human papillomavirus hpv vaccine diabetes mk q sleep disorders mk gaboxadol submissions cardiovascular vytorin ezetimibesimvastatin submitted q arthritisanalgesia arcoxia submitted q february merck announced discontinued phase ii clinical trials lead gabaa cid cid agonist compound treatment generalized anxiety company continuing research field anxiety ongoing study gaba agonist molecules timing development molecules certain april merck announced discontinuing development lead phosphodiesterase pde inhibitor compound phase ii clinical trials treatment asthma chronic obstructive pulmonary disease copd company continuing research field asthma copd ongoing study pde inhibitor molecules timing development molecules certainin august merck announced put phase clinical trials lead hiv integrase inhibitor compound hold company also continuing research field integrase inhibitors ongoing study integrase inhibitors timing development molecules certain november company announced discontinuing phase iii clinical development program substance p antagonist investigational product mk treatment depression phase iii clinical program halted compound failed demonstrate efficacy treatment depression merck remains committed neuroscience programs also november company announced discontinuing phase iii clinical development program investigational product mk treatment diabetes merck developing mk collaboration kyorin pharmaceutical co ltd clinical program halted recent findings mercks longterm safety assessment program identified rare form malignant tumors mice clinical relevance findings humans unknown merck continuing commitment diabetes research currently studying dpiv inhibitor diabetes company plans enter phase iii investigational compound second quarter research development expenses increased excluding effects exchange inflation expenses increased research development pharmaceutical industry inherently longterm process following data show unbroken trend yearto year increases companys research development spending period compounded annual growth rate research development research development expenditures millions merck co inc annual report acquired research company increased ownership banyu strengthening mercks position japan worlds secondlargest pharmaceutical market connection banyu shares acquisitions company recorded charges million acquired research associated products development acquisition date technological feasibility established alternative future use existed equity income affiliates equity income affiliates reflects performance companys joint ventures partnership returns azlp decrease equity income affiliates reflects lower partnership returns azlp primarily resulting impact generic competition prilosec decrease equity income affiliates primarily attributable impact companys share marketing launch expenses zetia ongoing research development expenses associated merckscheringplough partnerships income expense net increase income net primarily reflects million gain sale aggrastat product rights united states lower minority interest expense resulting banyu shares acquisitions realized gains companys investment portfolios relating favorable interest rate environment increase expense net primarily attributable losses investments partially offset lower minority interest expense earnings millions except per share amounts change change income continuing operations sales net income average total assets earnings per common share assuming dilution continuing operations companys effective income tax rate lower tax rate resulted change mix domestic foreign income includes impact fourth quarter restructuring costs new wholesaler distribution program income continuing operations declined compared decline income continuing operations percentage sales compared decline ratios driven effect changes product mix increased spending research development reduction also reflects impact new wholesaler distribution program restructuring costs charge acquired research net income percentage average total assets earnings per common share assuming dilution continuing operations declined lower relative declines earnings per common share assuming dilution continuing operations compared income continuing operations result treasury stock purchases selected joint venture affiliate information expand research base realize synergies combining capabilities opportunities assets company formed number joint ventures see note financial statements information company entered agreement astra ab astra develop market astra products united states thecompany astra formed equally owned joint venture developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining company astra restructured joint venture whereby company acquired astras interest joint venture renamed kbi inc kbi contributed kbis operating assets new us limited partnership named astra pharmaceuticals lp partnership company maintains limited partner interest partnership renamed astrazeneca lp azlp became exclusive distributor products kbi retained rights merck earns ongoing revenue based sales current future kbi products revenue billion billion billion respectively primarily relating sales nexium prilosec addition merck earns certain partnership returns recorded equity income affiliates returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing mercks share undistributed azlp gaap earnings returns aggregated million million million respectively decrease attributable reduction preferential return primarily resulting impact generic competition prilosec merck co inc annual report merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned joint venture expanded europe canada sales joint venture products follows millions gastrointestinal products products merck pasteur mrieux connaught aventis pasteur established owned joint venture market vaccines europe collaborate development combination vaccines distribution europe sales joint venture products follows millions hepatitis vaccines viral vaccines vaccines merck rhnepoulenc aventis combined animal health poultry genetics businesses form merial limited merial fully integrated animal health company standalone joint venture equally owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species sales joint venture products follows millions fipronil products avermectin products products company scheringplough corporation scheringplough entered agreements create separate equallyowned partnerships develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas cholesterolmanagement partnership agreements expanded include countries world excluding japan october ezetimibe first new class cholesterollowering agents approved united states zetia germany ezetrol zetia launched united states november following successful completion european union mutual recognition procedure ezetrol launched five european countriesgermany united kingdom switzerland sweden netherlands sales totaled million million september merckscheringplough pharmaceuticals submitted nda fda vytorin contains active ingredients zetia zocor november filing accepted fda standard review similar applications filed countries outside united states capital expenditures capital expenditures billion billion expenditures united states billion billion expenditures included million production facilities million research development facilities million environmental projects million administrative safety general site projects capital expenditures approved yet spent december billion capital expenditures estimated billion depreciation billion million million respectively applied locations united states capital expenditures millionsanalysis liquidity capital resources mercks strong financial profile enables company fully fund research development aggressively focus external alliances support inline products maximize upcoming launches providing significant cash returns shareholders cash provided operating activities billion companys primary source funds finance capital expenditures acquisitions banyu shares treasury stock purchases dividends paid stockholders december total worldwide cash investments billion including billion cash cash equivalents shortterm investments billion longterm investments selected data millions working capital total debt total liabilities equity cash provided operations total debt working capital levels adequate meet operating requirements company ratios total debt total liabilities equity cash provided operations total debt reflect strength companys operating cash flows ability company cover contractual obligations merck co inc annual report companys contractual obligations december follows payments due period millions total loans payable current portion longterm debt longterm debt operating leases loans payable current portion longterm debt includes million notes final maturity annual basis either repurchased holders option remarketing agent remarketed redeemed company loans payable current portion longterm debt also reflects million longdated notes subject repayment option holders annual basis required funding obligations relating companys pension postretirement benefit plans expected material companys billion shelf registration statement filed securities exchange commission issuance debt securities became effective february company issued million threeyear notes million variable rate notes shelf february company also entered interest rate swap contract effectively converts fixed rate notes floating rate instruments remaining capacity companys shelf registration statement approximately million companys strong financial position evidenced triplea credit ratings moodys standard poors outstanding debt issues provides high degree flexibility obtaining funds competitive terms ability finance ongoing operations primarily internally generated funds desirable high risks inherent research development required develop market innovative new products highly competitive nature pharmaceutical industry company participate offbalance sheet arrangements involving unconsolidated subsidiaries provide financing potentially expose company unrecorded financial obligations july board directors approved purchases time billion merck shares company purchased billion treasury shares previously authorized completed programs million program total treasury stock purchased billion period company purchased million shares total cost billion us dollar functional currency companys foreign subsidiaries significant portion companys revenues denominated foreign currencies merck relies sustained cash flows generated foreign sources support longterm commitment us dollarbased research development extent dollar value cash flows diminished result strengthening dollar companys ability fund research dollarbased strategic initiatives consistent level may impaired company established revenue hedging balance sheet risk management programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company partially hedge anticipated thirdparty sales expected occur planning cycle typically three years future company layer hedges time increasing portion sales hedged gets closer expected date transaction probable hedged transaction occur portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged risk manner merck manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows fully offset decline expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase value anticipated foreign currency cash flows weaker us dollar would result net benefit market value companys hedges would declined million million respectively uniform weakening us dollar december market value determined using foreign exchange option pricing model holding factors except exchange rates constant merck uses purchased local currency put options uniform weakening us dollar yield largest overall potential loss market value options sensitivity measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows primary objective balance sheet risk management program protect us dollar value foreign currency denominated net monetary assets effects volatility foreign exchange might occur prior conversion us dollars merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange amount us dollar cash flows derived net assets merck routinely enters contracts fully offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies themerck co inc annual report company enter forward contracts limited basis deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level company also uses forward contracts hedge changes fair value certain foreign currency denominated availableforsale securities attributable fluctuations foreign currency exchange rates sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly strengthened currency exposures company december income continuing operations taxes would declined million million respectively merck net long position relative major foreign currencies consideration forward contracts uniform strengthening us dollar yield largest overall potential net loss earnings due exchange measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows addition revenue hedging balance sheet risk management programs company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party three million notional amount payfloating receivefixed interest rate swap contracts designated hedges fair value changes million tenyear fiveyear threeyear fixed rate notes attributable changes benchmark libor swap rate swaps effectively convert fixedrate obligations floatingrate instruments company also party sevenyear combined interest rate currency swap contract entered converts variable rate foreign currency denominated investment variable rate us dollar investment swap contract hedges changes fair value investment attributable fluctuations exchange rates allowing company receive variable rate returns cash flows contracts reported operating activities consolidated statement cash flows companys investment portfolio includes cash equivalents shortterm investments market values significantly impacted changes interest rates market value companys medium longterm fixedrate investments modestly impacted changes us interest rates changes medium longterm us interest rates would significant impact market value companys fixedrate borrowings generally longer maturities sensitivity analysis measure potential changes market value companys investments debt related swap contracts change interest rates indicated one percentage point increase interest rates december would positively impacted net aggregate market value instruments million million respectively one percentage point decrease december would negatively impacted net aggregate market value million million respectively fair value companys debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair value companys investments determined using combination pricing duration models whereas duration linear approximation works well modest changes yields generates symmetrical result pricing models reflecting convexity priceyield relationship provide greater precision reflect asymmetry price movements interest rate changes opposite directions impact convexity pronounced longerterm maturities low interestrate environments critical accounting policies matters consolidated financial statements include certain amounts based managements best estimates judgments estimates used determining items provisions rebates discounts returns income taxes depreciable amortizable lives pension postretirement benefit plan assumptions amounts recorded contingencies environmental liabilities reserves uncertainty inherent estimates actual results may differ estimates application following accounting policies result accounting estimates potential significant impact financial statements revenue recognition revenues sales products recognized title risk loss passes customer revenues recorded net provisions rebates discounts returns established time sale accruals rebates discounts cover discounts result sales customer intermediary wholesale purchaser well rebates owed based upon contractual agreements legal requirements benefit providers including medicaid final dispensing product pharmacy benefit plan participant accruals estimated time sale based available information regarding portion sales rebates discounts earned adjusted appropriate specific known events reflecting prevailing contractual discount rate amounts accrued rebates discounts may adjusted trends significant events indicate adjustment appropriate accruals also adjusted reflect actual amounts paid credited upon validation claims data adjustments material results operations merck co inc annual report pensions postretirement benefit plans net pension postretirement benefit cost totaled million million pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations expected rate return plan assets company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated annually modified reflect prevailing market rate december portfolio highquality aa fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due december company changed discount rate us pension postretirement benefit plans expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data well actual returns companys plan assets applies adjustments reflect recent capital market experience using reference information company develops forwardlooking return expectations asset category weighted average expected longterm rate return targeted portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate result analysis companys expected rate return remained unchanged us pension postretirement benefit plans targeted investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments real estate cash investments portfolios equity weighting consistent longterm nature plans benefit obligation expected annual standard deviation returns targeted portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact net pension postretirement benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact net pension postretirement benefit cost company expect minimum pension funding requirement internal revenue code preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements unrecognized net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions expected returns based calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ companys expected returns recognized marketrelated value assets ratably fiveyear period total unrecognized net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees amortization total unrecognized net losses companys us plans december expected increase net pension postretirement benefit cost approximately million annually contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions see note financial statements information company continually evaluates risks assesses insurance needs relative market costs obtain insurance purchasing coverage appropriate provide protection losses company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable feasible predict outcome legal proceedings opinion company proceedings either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company addition time time federal state regulators seek information practices pharmaceutical industry feasible predict outcome requests information company expect inquiries material adverse effect financial position liquidity results operations company company party number proceedings brought comprehensive environmental response compensation liability act commonly known superfund legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties prps may jointly severally liable expected contribute determined merck co inc annual report company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying providing costs worldwide survey initially performed assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated estimates extent contamination site initially made preinvestigation stage liabilities potential cost remediation accrued time definitive information became available course investigations andor remedial efforts site estimates refined accruals adjusted accordingly estimates related accruals continue refined annually company believes compliance material respects applicable environmental laws regulations expenditures remediation environmental liabilities million estimated million years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december december respectively liabilities undiscounted consider potential recoveries insurers parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year taxes income companys effective tax rate based expected income statutory tax rates tax planning opportunities available various jurisdictions company operates event significant unusual onetime item recognized expected recognized companys operating results tax attributable item would separately calculated recorded time unusual onetime item significant judgment required determining companys effective tax rate evaluating tax positions company establishes reserves despite belief tax return positions fully supportable certain positions likely challenged may succeed company adjusts reserves light changing facts circumstances closing tax audit effective tax rate includes impact reserve provisions changes reserves considered appropriate well related interest rate applied companys quarterly operating results tax regulations require items included tax return different times items reflected financial statements result effective tax rate reflected financial statements different reported tax return differences permanent expenses deductible tax return timing differences depreciation expense timing differences create deferred tax assets liabilities deferred tax assets generally represent items used tax deduction credit tax return future years company already recorded tax benefit financial statements company establishes valuation allowances deferred tax assets amount expected future taxable income likely support use deduction credit deferred tax liabilities generally represent tax expense recognized financial statements payment deferred expense company already taken deduction tax return yet recognized expense financial statements december foreign earnings billion domestic earnings million retained indefinitely subsidiary companies reinvestment provision made income taxes would payable upon distribution earnings practicable determine amount related unrecognized deferred income tax liability recently issued accounting standards january financial accounting standards board fasb issued interpretation consolidation variable interest entities fin fin requires variable interest entity vie consolidated company subject majority risk loss vies activities entitled receive majority entitys residual returns december fasb issued revision fin fin r partially delayed effective date interpretation march added additional scope exceptions adoption fin r expected material impact companys financial position results operations cautionary factors may affect future results annual report written reports oral statements made time time company may contain socalled forwardlooking statements subject risks uncertainties one identify forwardlooking statements use words expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product approvals development programs one must carefully consider statement understand many factors could cause actual results differ companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially merck co inc annual report company assume obligation update forwardlooking statement one carefully evaluate statements light factors described companys filings securities exchange commission especially forms k q k item companys annual report year ended december filed march company discusses detail various important factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act prior filing year ended december reference made item companys annual report year ended december one understand possible predict identify factors consequently reader consider list complete statement potential risks uncertainties cash dividends paid per common share year th q rd q nd q st q common stock market prices th q rd q nd q st q high low high low principal market trading common stock new york stock exchange nyse symbol mrk common stock market price information based historical nyse market prices adjusted reflect spinoff medco health holders merck common stock close business august received shares medco health common stock every one share merck common stock held date august merck common stock began trade postdistribution basis condensed interim financial data millions except per share amounts th q rd q nd q st q sales materials production costs marketing administrative expenses research development expenses acquired research equity income affiliates income expense net income continuing operations taxes income continuing operations income discontinued operations net taxes net income basic earnings per common share continuing operations discontinued operations net income earnings per common share assuming dilution continuing operations discontinued operations net income sales materials production costs marketing administrative expenses research development expenses equity income affiliates income expense net income continuing operations taxes income continuing operations income discontinued operations net taxes net income basic earnings per common share continuing operations discontinued operations net income earnings per common share assuming dilution continuing operations discontinued operations net income amounts include impact implementation new distribution program us wholesalers restructuring costs related position eliminations amount add result rounding merck co inc annual report consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts sales costs expenses materials production marketing administrative research development acquired research equity income affiliates income expense net income continuing operations taxes taxes income income continuing operations income discontinued operations net taxes net income basic earnings per common share continuing operations discontinued operations net income earnings per common share assuming dilution continuing operations discontinued operations net income amount add result rounding consolidated statement retained earnings merck co inc subsidiaries years ended december millions balance january net income common stock dividends declared spinoff medco health balance december consolidated statement comprehensive income merck co inc subsidiaries years ended december millions net income comprehensive income lossnet unrealized loss gain derivatives net tax net income realization net unrealized loss gain investments net tax net income realization minimum pension liability net tax comprehensive income accompanying notes integral part consolidated financial statements merck co inc annual report consolidated balance sheet merck co inc subsidiaries december millions assets current assets cash cash equivalents shortterm investments accounts receivable inventories prepaid expenses taxes total current assets investments property plant equipment cost land buildings machinery equipment office furnishings construction progress less allowance depreciation goodwill intangibles net assets liabilities stockholders equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable total current liabilities longterm debt deferred income taxes noncurrent liabilities minority interests stockholders equity common stock one cent par value authorized shares issued shares shares paidin capital retained earnings accumulated comprehensive income loss less treasury stock cost shares shares total stockholders equity accompanying notes integral part consolidated financial statement merck co inc annual report consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities continuing operations net income less income discontinued operations net taxes income continuing operations adjustments reconcile income continuing operations net cash provided operating activities continuing operations acquired research depreciation amortization deferred income taxes net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities net cash provided operating activities continuing operations cash flows investing activities continuing operations capital expenditures purchase securities subsidiaries investments proceeds sale securities subsidiaries investments acquisitions banyu shares net cash used investing activities continuing operations cash flows financing activities continuing operations net change shortterm borrowings proceeds issuance debt payments debt purchase treasury stock dividends paid stockholders proceeds exercise stock options net cash used financing activities continuing operations effect exchange rate changes cash cash equivalents discontinued operations net cash provided medco health dividend received medco health net intercompany settlements cash transferred net cash provided discontinued operations net decrease increase cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statement merck co inc annual report notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations merck global researchdriven pharmaceutical products company discovers develops manufactures markets broad range innovative products improve human animal health directly joint ventures companys products include therapeutic preventive agents generally sold prescription treatment human disorders august merck completed spinoff medco health solutions inc medco health following spinoff companys prior period consolidated statements income cash flows related disclosures restated present results medco health separately discontinued operations december consolidated balance sheet prior period consolidated statements retained earnings comprehensive income related disclosures restated result spinoff product sales reflect sales medco health thirdparty sales based upon net selling price merck medco health summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained controlling interest determined majority ownership interest absence substantive thirdparty participating rights consolidated subsidiaries merck ownership less outside stockholders interests shown minority interests investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis foreign currency translation us dollar functional currency companys foreign subsidiaries cash cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories substantially domestic pharmaceutical inventories valued lower lastin firstout lifo cost market book tax purposes foreign pharmaceutical inventories valued lower firstin firstout fifo cost market inventories consist currently marketed products certain products awaiting regulatory approval evaluating realizable value inventory products awaiting regulatory approval company considers probability revenue obtained future sale related inventory together status product within regulatory approval process investments investments classified availableforsale reported fair value unrealized gains losses extent hedged reported net tax minority interests accumulated comprehensive income investments debt securities classified heldtomaturity consistent managements intent reported cost impairment losses charged income expense net otherthantemporary declines fair value company considers available evidence evaluating potential impairment investments including duration extent fair value less cost companys ability intent hold investment revenue recognition revenues sales products recognized title risk loss passes customer revenues recorded net provisions rebates discounts returns established time sale depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings goodwill intangibles goodwill represents excess acquisition costs fair value net assets businesses purchased effective january company adopted provisions statement financial accounting standards goodwill intangible assets fas addresses recognition measurement goodwill intangibles subsequent business combination accordance fas goodwill associated acquisitions subsequent june amortized see note effective january goodwill existing june amortized rather assigned reporting units within companys segments evaluated impairment least annual basis using fair value based test amortization expense goodwill recorded reported income continuing operations would increased million basic earnings per common share continuing operations earnings per common share assuming dilution continuing operations reported net income would increased million basic earnings per common share earnings per common share assuming dilution acquired intangibles recorded cost amortized straightline basis estimated useful lives see note events circumstances warrant review company assess recoverability future operations intangibles using undiscounted cash flows derived lowest appropriate asset groupings generally subsidiary level impairments recognized operating results extent carrying value exceeds fair value determined based net present value estimated future cash flows merck co inc annual report stockbased compensation employee stockbased compensation recognized using intrinsic value method generally employee stock options granted purchase shares company stock fair market value time grant accordingly compensation expense recognized companys stockbased compensation plans employee performancebased awards options granted employees certain equity method investees total significant effect net income earnings per common share company applied fair value method recognizing employee stockbased compensation follows years ended december net income reported compensation expense net tax reported fair value method pro forma net income earnings per common share continuing operations assuming dilution reported assuming dilution pro forma earnings per common share basic reported basic pro forma assuming dilution reported assuming dilution pro forma connection medco health spinoff options granted medco health employees prior february options granted february became fully vested accordance original terms grants result pro forma compensation expense reflects accelerated vesting options addition certain stock options granted medco health employees converted medco health options terms amounts maintained option holders positions therefore pro forma compensation expense options reflected date spinoff average fair value employee nonemployee director options granted respectively fair value estimated using blackscholes optionpricing model based weighted average market price grant date following weighted average assumptions years ended december dividend yield riskfree interest rate volatility expected life years use estimates consolidated financial statements prepared conformity accounting principles generally accepted united states gaap accordingly include certain amounts based managements best estimates judgments estimates used determining items provisions rebates discounts returns income taxes depreciable amortizable lives pension postretirement benefit plan assumptions amounts recorded contingencies environmental liabilities reserves uncertainty inherent estimates actual results may differ estimates reclassifications certain reclassifications made prior year amounts conform current year presentation acquisitions discontinued operations restructuring january company wholly owned subsidiary msd japan co ltd launched tender offer acquire remaining common shares banyu pharmaceutical co ltd banyu already march company received tenders million shares bringing ownership outstanding banyu common shares purchase price approximating billion october company completed second tender offer remaining shares banyu bringing mercks ownership outstanding banyu common shares offer made purchase price approximating million acquisitions allow company enhance position japanese market worlds secondlargest pharmaceutical market companys acquisitions banyu shares accounted purchase method accordingly banyus results operations included companys consolidated results operations since march october respectively pro forma information provided impact transactions material effect companys consolidated results operations aggregate purchase price allocated based upon fair values portion assets liabilities acquired allocation aggregate purchase price resulted reversal billion minority interest liability recognition million intangibles million goodwill million deferred income tax liabilities million net assets principally property plant equipment intangibles included million inline product rights year weighted average useful life million representing year life tradename connection transactions company also recorded charges million acquiredmerck co inc annual report research associated products development acquisition date technological feasibility established alternative future use existed approximately million total acquired research charge related merck products banyu developing sale japanese market significant vioxx products merck choose exclusively license rights banyu event generally would reimburse banyu associated research development expenditures accordingly products valued using cost approach adjusted reflect probability regulatory approval remaining portion acquired research charge represents banyu developed product candidates fair value product determined based upon present value projected future cash flows utilizing income approach reflecting appropriate riskadjusted discount rate based applicable products stage completion probability technical marketing success july company completed acquisition rosetta inpharmatics inc rosetta leading informational genomics company taxfree reorganization rosetta designed developed several unique technologies efficiently analyze gene data predict medical compounds interact different kinds cells body therefore allowing merck scientists precisely select drug targets potentially accelerate development process acquisition accounted purchase method accordingly rosettas results operations included companys since acquisition date pro forma information provided transaction material impact companys results operations financial position accordance may agreement plan merger agreement share outstanding rosetta stock converted shares merck stock resulting issuance company approximately million shares common stock aggregate purchase price transaction approximated million including million common share value million representing employee stock options valued agreement date million estimated transaction fees allocation purchase price resulted tangible assets million consisting primarily cash shortterm investments intangible assets million liabilities assumed million including deferred tax liabilities million associated intangible assets goodwill totaling million intangibles weighted average useful life approximating five years aggregate major class include million patent rights million contractual agreements accordance fas goodwill associated rosetta acquisition amortized august merck completed spinoff medco health spinoff effected way pro rata dividend merck stockholders holders merck common stock close business august received dividend shares medco health common stock every one share merck common stock held date fractional shares medco health common stock issued shareholders entitled fractional share medco health common stock distribution received cash value instead based letter ruling merck received us internal revenue service receipt medco health shares distribution taxfree us federal income tax purposes cash received lieu fractional shares taxable prior spinoff merck received billion dividend medco health merck paid million settlement net intercompany payable medco health addition date spinoff million cash cash equivalents included net assets medco health spun summarized financial information discontinued operations follows years ended december total net revenues income taxes taxes income includes operations august following summary assets liabilities discontinued operations spun august assets cash cash equivalents current assets property plant equipment net goodwill intangibles net assets liabilities current liabilities longterm debt deferred income taxes net assets transferred company accelerated efforts fundamentally lower cost structure companywide initiatives october company announced reduction positions expected completed approximately positions eliminated december company recorded restructuring costs million marketing administrative expense million related employee severance benefits million related curtailment settlement termination charges companys pension postretirement benefit plans see note million related modification terms certain employees stock option grants payments employee severance benefits million leaving remaining accrued balance million december additional restructuring costs expected incurred merck co inc annual report joint ventures equity method affiliates merck entered agreement astra ab astra develop market astras products royaltybearing license companys total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining merck astra completed restructuring ownership operations joint venture whereby company acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc astrazeneca merger became exclusive distributor products kbi retained rights maintaining limited partner interest azlp merck consent protective rights intended preserve business economic interests including restrictions power general partner make certain distributions dispositions furthermore limited events default additional rights granted company including powers direct actions remove replace partnerships chief executive officer chief financial officer merck earns ongoing revenue based sales current future kbi products revenue billion billion billion respectively primarily relating sales nexium prilosec addition merck earns certain partnership returns recorded equity income affiliates returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing mercks share undistributed azlp gaap earnings returns aggregated million million million respectively decrease attributable reduction preferential return primarily resulting impact generic competition prilosec astrazeneca merger triggers partial redemption mercks limited partnership interest upon redemption azlp distribute kbi amount based primarily multiple mercks average annual variable returns derived sales former astra usa inc products three years prior redemption limited partner share agreed value conjunction restructuring payment million deferred astra purchased option asset option buy mercks interest kbi products excluding gastrointestinal medicines nexium prilosec asset option exercisable exercise price equal net present value march projected future pretax revenue received company kbi products appraised value merck also right require astra purchase interest appraised value addition company granted astra option buy mercks common stock interest kbi exercise price based net present value estimated future net sales nexium prilosec option exercisable two years astras purchase mercks interest kbi products astrazeneca merger constituted trigger event kbi restructuring agreements result merger exchange mercks relinquishment rights future astra products existing pending us patents time merger astra paid million advance payment subject trueup calculation may require repayment portion amount trueup amount directly dependent fair market value astra product rights retained company accordingly recognition contingent income deferred realizable amount determinable anticipated prior provisions kbi restructuring agreements trigger event occurred sum limited partner share agreed value appraised value trueup amount guaranteed minimum billion distribution limited partner share agreed value payment trueup amount occur astrazenecas purchase mercks interest kbi products contingent upon exercise either mercks option astrazenecas option therefore payment appraised value may may occur merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned venture expanded europe canada sales product marketed joint venture million million million merck pasteur mrieux connaught aventis pasteur established equallyowned joint venture market vaccines europe collaborate development combination vaccines distribution europe joint venture vaccine sales million million million merck rhnepoulenc aventis combined animal health poultry genetics businesses form merial limited merial fully integrated animal health company standalone joint venture equally owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species merial sales billion billion billion merck co inc annual report company scheringplough corporation scheringplough entered agreements create separate equallyowned partnerships develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas cholesterolmanagement partnership agreements expanded include countries world excluding japan october ezetimibe first new class cholesterollowering agents approved united states zetia germany ezetrol zetia launched united states november following successful completion european union mutual recognition procedure ezetrol launched five european countries germany united kingdom switzerland sweden netherlands sales totaled million million september merckscheringplough pharmaceuticals submitted new drug application us food drug administration fda vytorin contains active ingredients zetia zocor november filing accepted fda standard review similar applications filed countries outside united states january merckscheringplough respiratory partnership reported results phase iii clinical trials fixed combination tablet containing singulair claritin scheringploughs nonsedating antihistamine demonstrate sufficient added benefits treatment seasonal allergic rhinitis investments affiliates accounted using equity method including joint ventures totaled billion december respectively amounts reported assets dividends distributions received affiliates million million million financial instruments upon adoption statement financial accounting standards accounting derivative instruments hedging activities fas january company recorded favorable cumulative effect accounting change million tax comprehensive income loss representing mark fair value purchased local currency put options see note cumulative effect accounting change recorded net income significant foreign currency risk management us dollar functional currency companys foreign subsidiaries significant portion companys revenues denominated foreign currencies merck relies sustained cash flows generated foreign sources support longterm commitment us dollarbased research development extent dollar value cash flows diminished result strengthening dollar companys ability fund research dollarbased strategic initiatives consistent level may impaired company established revenue hedging balance sheet risk management programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company partially hedge anticipated thirdparty sales expected occur planning cycle typically three years future company layer hedges time increasing portion sales hedged gets closer expected date transaction probable hedged transaction occur portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged risk manner merck manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows fully offset decline expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase value anticipated foreign currency cash flows first four months changes options intrinsic value deferred accumulated comprehensive income aoci recognition hedged anticipated revenue amounts associated option time value excluded designated hedge relationship marked fair value earnings significant effective may permitted fas implementation guidance finalized june designated hedge relationship based total changes options cash flows accordingly entire fair value change options deferred aoci reclassified sales hedged anticipated revenue recognized hedge relationship perfectly effective therefore hedge ineffectiveness recorded fair values purchased currency options reported accounts receivable assets primary objective balance sheet risk management program protect us dollar value foreign currency denominated net monetary assets effects volatility foreign exchange might occur prior conversion us dollars merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange amount us dollar cash flows derived net assets merck routinely enters contracts fully offset effects exchange exposures merck co inc annual report denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts limited basis deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level foreign currency denominated monetary assets liabilities remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year company also uses forward contracts hedge changes fair value certain foreign currency denominated availableforsale securities attributable fluctuations foreign currency exchange rates changes fair value hedged securities due fluctuations spot rates offset income expense net fair value changes forward contracts attributable spot rate fluctuations hedge ineffectiveness material changes contracts fair value due spotforward differences excluded designated hedge relationship recognized income expense net amounts significant years ended december fair values forward exchange contracts reported following four balance sheet line items accounts receivable current portion gain position assets noncurrent portion gain position accrued current liabilities current portion loss position deferred income taxes noncurrent liabilities noncurrent portion loss position interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk company entered tenyear million notional amount payfloating receivefixed interest rate swap contract designated hedge fair value changes million tenyear fixed rate notes attributable changes benchmark london interbank offered rate libor swap rate company entered similar fiveyear threeyear million notional amount payfloating receivefixed interest rate swap contracts designated fair value hedges million fiveyear threeyear fixed rate notes swaps effectively convert fixedrate obligations floatingrate instruments fair value changes notes fully offset interest expense fair value changes swap contracts company also party sevenyear combined interest rate currency swap contract entered converts variable rate foreign currency denominated investment variable rate us dollar investment interest rate component swap designated hedge currency swap component designated hedge changes fair value investment attributable exchange accordingly changes fair value investment due fluctuations spot rates offset income expense net fair value changes currency swap hedge ineffectiveness significant fair values contracts reported accounts receivable assets accrued current liabilities deferred income taxes noncurrent liabilities fair value financial instruments summarized carrying values fair values companys financial instruments december fair values estimated based market prices available dealer quotes carrying fair carrying fair value value value value assets cash cash equivalents shortterm investments longterm investments purchased currency options forward exchange contracts currency swap interest rate swaps liabilities loans payable current portion long term debt longterm debt forward exchange contracts currency swap summary carrying values fair values companys investments december follows carrying fair carrying fair value value value value availableforsale debt securities equity securities heldtomaturity securities merck co inc annual report summary december gross unrealized gains losses companys availableforsale investments recorded net tax minority interests aoci follows gross unrealized gross unrealized gains losses gains losses debt securities equity securities availableforsale debt securities heldtomaturity securities maturing within one year totaled billion million respectively december remaining debt securities billion mature within five years december million heldtomaturity securities matured set million nontransferable note obligations issued company also matured concentrations credit risk part ongoing control procedures company monitors concentrations credit risk associated corporate issuers securities financial institutions conducts business credit risk minimal credit exposure limits established avoid concentration single issuer institution three drug wholesalers represented aggregate approximately onefifth companys accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales inventories inventories december consisted finished goods raw materials work process supplies total approximates current cost reduction lifo cost recognized inventories assets inventories valued lifo method comprised approximately inventories december respectively amounts recognized assets consist inventories held preparation product launches expected sold within one year reduction finished goods primarily attributable spinoff medco health intangibles intangibles december consisted customer relationships medco health patents product rights total acquired cost customer relationships medco health patents product rights total accumulated amortization aggregate amortization expense recorded materials production expense income expense net totaled million million million estimated aggregate amortization expense next five years follows million million million million million loans payable longterm debt commitments loans payable december consisted primarily million billion respectively commercial paper borrowings million notes annual interest rate resets final maturity annual basis notes either repurchased holders option remarketing agent remarketed redeemed company december loans payable also reflected million million respectively longdated notes subject repayment option holders annual basis december loans payable also included million variable rate borrowing due weighted average interest rate borrowings december respectively longterm debt december consisted astra note due notes due notes due notes due euronotes due debentures due debentures due debentures due variable rate borrowing due merck co inc annual report december company party interest rate swap contracts effectively convert december fixed rate notes floating rate instruments see note december consisted primarily million borrowings variable rates averaging respectively december million million borrowings subject repayment option holders beginning respectively years also consisted foreign borrowings varying rates aggregate maturities longterm debt next five years follows million billion million million billion rental expense companys operating leases net sublease income million minimum aggregate rental commitments noncancellable leases follows million million million million million thereafter million company significant capital leases contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions company continually evaluates risks assesses insurance needs relative market costs obtain insurance purchasing coverage appropriate provide protection losses company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable beginning company named number antitrust suits certain certified class actions instituted nations retail pharmacies consumers several states alleging antitrust violations actions except pending state courts consolidated pretrial purposes federal court chicago illinois company several defendants settled federal class action represented single largest group claims since time company settled substantially remaining cases satisfactory terms company engaged conspiracy admission wrongdoing made included settlement agreements feasible predict final outcome remaining cases opinion company proceedings ultimately result liability would material adverse effect companys financial position results operations liquidity previously disclosed company advised us department justice investigating marketing selling activities company pharmaceutical manufacturers connection investigation previously disclosed government served subpoena company production documents related company marketing sales activities subpoena seeks substantially information government previously sought company working government respond appropriately subpoena informational requests company also received civil investigative demand cid attorney general texas cid seeks production documents information regarding companys marketing selling activities relating texas company working texas attorney generals office respond appropriately cid previously disclosed company joined ongoing litigation alleging manipulation pharmaceutical manufacturers average wholesale prices awp sometimes used calculations determine public private sector reimbursement levels judicial panel multidistrict litigation ordered transfer consolidation pending federal awp cases federal court boston massachusetts plaintiffs filed one consolidated class action complaint aggregated claims previously filed various federal district court actions also expanded number manufacturers include like company defendants prior pending case may court granted companys motion dismiss consolidated class action dismissed company class action case subsequent companys dismissal plaintiffs filed amended consolidated class action complaint name company defendant company thirty pharmaceutical manufacturers remain defendants three similar complaints pending federal court massachusetts filed new york counties suffolk rockland westchester company believes lawsuits without merit vigorously defending previously disclosed january us department justice notified federal court new orleans louisiana going intervene pending federal false claims act case filed seal december company court issued order unsealing complaint filed physician louisiana ordered complaint served complaint alleges companys discounting pepcid certain louisiana hospitals led increases costs medicaid company believes complaint without merit vigorously defend federal state lawsuits involving numerous individual claims well putative class actions filed company respect vioxx lawsuits also name defendant pfizer inc markets competing product certain lawsuits include allegations regarding gastrointestinal bleeding cardiovascular events kidney damage lawsuits filed federal courts well number state courts cases jurisdictions proceeding separately actions filed state courts california new jersey transferred single judge state coordinated proceedings company anticipates one lawsuits various jurisdictions merck co inc annual report may go trial first half litigation inherently subject uncertainties assurance given outcome given trial however company believes lawsuits without merit vigorously defend number purported class action lawsuits filed several individual shareholders united states district court eastern district louisiana naming defendants company several current former officers company alleging defendants made false misleading statements regarding companys drug vioxx violation federal securities laws plaintiffs request certification class purchasers companys common stock may october seek unspecified compensatory damages costs suit including attorney fees company believes lawsuits without merit vigorously defend company party claims brought consumer protection act united kingdom allege certain children suffer variety conditions result vaccinated various bivalent vaccines measles rubella andor trivalent vaccines measles mumps rubella including companys mmr ii pharmaceutical companies also sued claimants allege various adverse consequences including autism without inflammatory bowel disease epilepsy diabetes encephalitis encephalopathy chronic fatigue syndrome connection claims eight lead cases selected trial scheduled commence april two company six pharmaceutical companies trial eight cases initially limited issues causation defect conditions autistic spectrum disorders without inflammatory bowel disease early september legal services commission announced decision withdraw public funding litigation brought claimants decision confirmed appeal funding review committee september april trial date vacated claims stayed pending outcome february hearing judicial review funding withdrawal decision company believes lawsuits without merit vigorously defend company also party individual class action product liability lawsuits claims united states involving pediatric vaccines ie hepatitis b vaccine haemophilus influenza type b vaccine contained thimerosal preservative used vaccines defendants include vaccine manufacturers produced pediatric vaccines containing thimerosal well manufacturers thimerosal actions plaintiffs allege among things suffered neurological injuries result thimerosal introduced developing bodies company successful many cases either dismissed stayed ground national vaccine injury compensation program nvicp prohibits person filing maintaining civil action seeking damages vaccine manufacturer vaccinerelated injuries unless petition first filed united states court federal claims number similar cases mmr ii alone andor thimerosal containing vaccines filed united states court federal claims nvicp determination first general causation issues company believes lawsuits claims without merit vigorously defend proceedings party time time generic manufacturers pharmaceutical products file abbreviated new drug applications andas fda seeking market generic forms company products prior expiration relevant patents owned company generic pharmaceutical manufacturers submitted andas fda seeking market united states generic form fosamax prilosec vioxx prior expiration companys astrazenecas case prilosec patents concerning products generic companies andas generally include allegations noninfringement invalidity unenforceability patents generic manufacturers received fda approval market generic form prilosec company filed patent infringement suits federal court companies filing andas generic alendronate rofecoxib astrazeneca company filed patent infringement suits federal court companies filing andas generic omeprazole similar patent challenges exist certain foreign jurisdictions company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration dates patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products trial united states respect alendronate daily product concluded november november decision issued us district court delaware finding companys patent valid infringed october us court appeals federal circuit affirmed validity infringement companys basic us patent covering use alendronate form request rehearing denied trial united states involving alendronate weekly product held march august us district court delaware upheld validity companys us patent covering weekly administration alendronate result courts decision patent valid infringed teva pharmaceuticals usa incs teva abbreviated new drug application filing courts decision appealed teva january high court justice england wales held patents company protecting alendronate daily weekly products invalid united kingdom november court appeals england wales affirmed ruling high court justice england wales protection generic companies referencing companys data weekly alendronate united kingdom may available provisions law grant period exclusivity original submitter data generic company sought judicial review decision licensing authority united kingdom rely upon companys weekly alendronate data seek approval generic alendronate mg product years approval companys weekly alendronate product granted company served interested party intends take appropriate action protect rights merck co inc annual report case omeprazole trial court united states rendered opinion october upholding validity companys astrazenecas patents covering stabilized formulation omeprazole ruling one defendants omeprazole product infringe patents three defendants products found infringe formulation patents december us court appeals federal circuit affirmed decision trial court respect certain generic manufacturers omeprazole products trial date yet set case rofecoxib anda filed including allegations noninfringement invalidity unenforceability companys rofecoxib patents previously disclosed company filed patent infringement lawsuit district court delaware august trial set october previously disclosed company named defendant number purported class action lawsuits consolidated single judge shareholder derivative action involve claims related companys revenue recognition practice retail copayments paid individuals medco health provides pharmaceutical benefits class action lawsuit amended add claims company medco health certain officers directors relating rebates received medco health medco healths independent status shareholder derivative action amended add arthur andersen llp defendant add certain new allegations relate claims certain individual defendants breached fiduciary duty failing prevent conduct issue previously disclosed gruer cases discussed antitrust claims pending northern district illinois qui tam actions us attorneys office eastern district pennsylvania intervened medco health complaint seeks monetary damages company directors defendants lawsuit unspecified amount well injunctive relief part spinoff medco health medco health assumed responsibility portion potential damages settlement payments paid connection litigation company believes lawsuits without merit vigorously defend prior spinoff medco health company medco health agreed settle class action basis series lawsuits asserting violations employee retirement income security act erisa company medco health certain plaintiffs counsel filed settlement agreement federal district court new york cases commenced number plaintiffs including participants number pharmaceutical benefit plans medco health pharmacy benefit manager well trustees plans consolidated proposed class settlement agreed plaintiffs five cases gruer cases filed medco health company proposed settlement company medco health agreed pay total million medco health agreed modify certain business practices continue certain specified business practices period five years financial compensation intended benefit members settlement class includes erisa plans medco health administered pharmacy benefit time since december court preliminarily approved settlement held hearing hear objections fairness proposed settlement class member representatives currently certain class member plans indicated participate settlement court yet approved settlement determined number class member plans properly elected participate settlement approved settlement becomes final district court grants final approval appeals resolved medco health company agreed proposed settlement order avoid significant cost distraction protracted litigation gruer cases similar claims pending pharmaceutical benefit managers alleged medco health erisa fiduciary company partyininterest within meaning erisa plaintiffs asserted company medco health breached duties engaged prohibited transactions result filling prescriptions companys drugs increase companys market share among things plaintiffs demanded medco health company disgorge unlawfully obtained profits relief addition among cases consolidated new york one plaintiff also alleged based essentially factual allegations gruer cases medco health company violated federal state racketeering laws different plaintiff seeking represent california citizens alleged medco health company violated california unfair competition law attorney one plaintiffs indicated may assert claims medco health company others allege violations sherman act clayton act various state antitrust laws based alleged conspiracies suppress price competition unlawful combinations allegedly resulting higher pharmaceutical prices spinoff medco health medco health assumed substantially liability exposure matters discussed foregoing three paragraphs company believes cases defended medco health without merit various legal proceedings principally product liability intellectual property suits involving company pending feasible predict outcome proceedings proceedings discussed opinion company proceedings either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company addition time time federal state regulators seek information practices pharmaceutical industry feasible predict outcome requests information company expect inquiries material adverse effect financial position liquidity results operations company merck co inc annual report company party number proceedings brought comprehensive environmental response compensation liability act commonly known superfund legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties prps may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying providing costs worldwide survey initially performed assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated estimates extent contamination site initially made preinvestigation stage liabilities potential cost remediation accrued time definitive information became available course investigations andor remedial efforts site estimates refined accruals adjusted accordingly estimates related accruals continue refined annually managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries insurers parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year preferred stock subsidiary companies wholly owned subsidiary company issued billion par value variable rate preferred units units redeemable par value plus accrued dividends option issuer time addition credit ratings companys unsecured senior debt obligations fall specified levels likelihood company believes remote holders preferred units would ability require redemption preferred units preferred securities held subsidiary level included minority interests consolidated financial statements connection restructuring ami see note company assumed billion par value preferred stock obligation dividend rate per annum carried kbi included minority interests small portion preferred stock carried kbi convertible kbi common shares none preferred securities convertible companys common shares therefore included common shares issuable purposes computing earnings per common share assuming dilution see note stockholders equity paidin capital increased million million million respectively increase includes million resulting shares issued equivalent employee stock options assumed connection rosetta acquisition see note remaining increases primarily reflect impact shares issued upon exercise stock options related income tax benefits summary treasury stock transactions shares millions follows shares cost shares cost shares cost balance jan purchases issuances balance dec issued primarily stock option plans december million shares preferred stock without par value authorized none issued stock option plans company stock option plans employees nonemployee directors employees certain companys equity method investees may granted options purchase shares company common stock fair market value time grant plans approved companys shareholders option grants beginning generally vest ratably three years grants prior generally vest five years options expire ten years date grant companys stock option plan employees also provides granting performancebased stock awards connection medco health spinoff number exercise prices outstanding options proportionately adjusted maintain option holders positions spinoff result adjustment number outstanding options increased millionshares average exercise price decreased approximately addition certain stock options granted medco health employees converted medco health options terms amounts maintained option holders positions merck co inc annual report connection mercks acquisition rosetta stock options outstanding acquisition date converted options purchase shares company common stock equivalent value summarized information relative companys stock option plans shares thousands follows number average shares price outstanding december granted exercised forfeited equivalent options assumed outstanding december granted exercised forfeited outstanding december granted exercised forfeited converted medco health spinoff adjustment outstanding december weighted average exercise price includes million options converted medco health options number shares average price options exercisable december million shares million shares million shares respectively december million shares million shares respectively available future grants terms plans summarized information stock options outstanding exercisable december shares thousands follows outstanding exercisable exercise price number average average number average range shares life price shares price weighted average contractual life remaining years weighted average exercise price pension postretirement benefit plans company defined benefit pension plans covering eligible employees united states certain international subsidiaries pension benefits united states based formula considers final average pay years credited service addition company provides medical dental life insurance benefits principally eligible us retirees similar benefits dependents postretirement benefit plans company uses december measurement date us pension postretirement benefit plans effects medicare prescription drug improvement modernization act act recognized net cost benefit obligation related disclosures us postretirement benefit plans specific authoritative guidance accounting federal subsidy act pending guidance issued could require company change previously reported informationin company changed participant contributions service recognized eligibility postretirement benefit plans amendments reduced benefit obligation million generated curtailment gains million million respectively addition company recorded settlement loss million pension plans curtailment loss million postretirement benefit plans resulting reductions employment levels primarily connection restructuring activities company also recorded termination charges million pension plans million postretirement benefit plans related expanded eligibility certain employees exiting restructuring action see note net cost companys pension plans consisted following components years ended december service cost interest cost expected return plan assets net amortization settlements termination benefits net pension cost net pension cost attributable us plans included table million million million merck co inc annual report net cost postretirement benefits pensions consisted following components years ended december service cost interest cost expected return plan assets net amortization curtailments termination benefits net postretirement benefit cost cost health care life insurance benefits active employees million million million summarized information changes plan assets benefit obligation follows postretirement pension benefits benefits fair value plan assets january actual return plan assets company contributions benefits paid plan assets discontinued operations fair value plan assets december benefit obligation january service cost interest cost actuarial losses benefits paid plan amendments curtailments termination benefits discontinued operations benefit obligation december fair value us pension plan assets included preceding table billion billion pension benefit obligation us plans included table billion billion reconciliation plans funded status net asset liability recognized december follows postretirement pension benefits benefits plan assets less benefit obligation unrecognized net loss unrecognized plan changes net asset liability recognized assets accrued current liabilities deferred income taxes noncurrent liabilities accumulated comprehensive loss weighted average asset allocations investment portfolio us pension postretirement benefit plans december follows u equities international equities fixed income investments real estate cash investments merck co inc annual report targeted investment portfolio allocated us equities international equities fixedincome investments real estate cash investments portfolios equity weighting consistent longterm nature plans benefit obligation expected annual standard deviation returns targeted portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests contributions pension plans postretirement benefit plans expected million million respectively contributions us pension plans expected million expected benefit payments us follows postretirement pension benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service december accumulated benefit obligation billion billion respectively pension plans billion billion respectively us pension plans company minimum pension liability million million december respectively representing extent accumulated benefit obligation exceeded plan assets certain companys pension plans decrease minimum pension liability recorded comprehensive income loss assets primarily reflects increase fair value plan assets certain plans resulting favorable asset returns pension plans benefit obligations excess plan assets december fair value plan assets billion billion respectively benefit obligation billion billion respectively plans accumulated benefit obligations excess plan assets december fair value plan assets million million respectively accumulated benefit obligation million billion respectively unrecognized net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions unrecognized net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees amortization unrecognized net losses companys us plans december expected increase net pension postretirement benefit cost approximately million annually company reassesses benefit plan assumptions regular basis assumptions used determining us plan information follows pension postretirement benefits december net cost discount rate expected rate return plan assets salary growth rate benefit obligation discount rate salary growth rate expected rate return us pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers long term compound annualized returns historical market data well actual returns companys plan assets applies adjustments reflect recent capital market experience using reference information company develops forward looking return expectations asset category weighted average expected longterm rate return targeted portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate result analysis companys expected rate return remain unchanged us pension postretirement benefit plans weighted average assumptions used determining us international pension plan information follows december net costdiscount rate expected rate return plan assets salary growth rate benefit obligation discount rate salary growth rate health care cost trend rate assumptions postretirement benefit plans follows december health care cost trend rate assumed next year rate cost trend rate assumed decline year rate reached ultimate trend rate one percentage point change health care cost trend rate would following effects one percentage point increase decrease effect total service interest cost components effect benefit obligation merck co inc annual report income expense net years ended december interest income interest expense exchange gains minority interests amortization goodwill intangibles net minority interests include third parties share exchange gains losses arising translation financial statements us dollars reduced minority interests attributable effect banyu shares acquisitions see note result lower dividends variable rate preferred units see note well decreased minority interest expense associated banyu increase net primarily reflects million gain sale aggrastat product rights united states realized gains companys investment portfolios relating favorable interest rate environment interest paid million million million taxes income reconciliation companys effective tax rate us statutory rate follows tax rate amount us statutory rate applied income continuing operations taxes differential arising foreign earnings tax exemption puerto rico operations state taxes domestic companies contributed approximately consolidated income continuing operations taxes taxes income continuing operations consisted years ended december current provision federal foreign state deferred provision federal foreign state deferred income taxes december consisted assets liabilities assets liabilities intangibles inventory related accelerated depreciation advance payment equity investments pensions opeb compensation related subtotal valuation allowance total deferred taxes net deferred tax liabilities recognized prepaid expenses taxes assets income taxes payable deferred income taxes noncurrent liabilities reduction net deferred tax liabilities primarily attributable spinoff medco health income taxes paid billion billion billion respectively stock option exercises reduced income taxes paid million million million respectively december foreign earnings billion domestic earnings million retained indefinitely subsidiary companies reinvestment provision made income taxes would payable upon distribution earnings practicable determine amount related unrecognized deferred income tax liability earnings include income manufacturing operations ireland taxexempt taxed thereafter addition company subsidiaries operating puerto rico singapore tax incentive grants expire respectively companys federal income tax returns audited merck co inc annual report earnings per share weighted average common shares used computations basic earnings per common share earnings per common share assuming dilution shares millions follows years ended december average common shares outstanding common shares issuable average common shares outstanding assuming dilution issuable primarily stock option plans comprehensive income upon adoption fas january company recorded favorable cumulative effect accounting change million comprehensive income loss amount represented mark fair value purchased local currency put options maturing throughout hedged anticipated foreign currency denominated sales period december million deferred loss associated options maturing next months hedge anticipated foreign currency denominated sales period components comprehensive income loss follows pretax tax tax year ended december net unrealized loss derivatives net loss realization derivatives net unrealized gain investments net income realization investments minimum pension liability year ended december net unrealized loss derivatives net income realization derivatives net unrealized gain investments net income realization investments minimum pension liability year ended december cumulative effect accounting change net unrealized gain derivatives net income realization derivatives net unrealized gain investments net income realization investments minimum pension liability net applicable minority interest components accumulated comprehensive income loss follows december net unrealized loss derivatives net unrealized gain investments minimum pension liability segment reporting companys operations principally managed products basis merck pharmaceutical segment includes products marketed either directly joint ventures products consist therapeutic preventive agents sold prescription treatment human disorders merck sells human health products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations institutions includes nonreportable human animal health segments revenues profits segments follows merck pharm aceutical total year ended december segment revenues segment profits included segment profits equity income affiliates depreciation amortization year ended december segment revenues segment profits included segment profits equity income affiliates depreciation amortization year ended december segment revenues segment profits included segment profits equity income affiliates depreciation amortization merck co inc annual report segment profits comprised segment revenues less certain elements materials production costs operating expenses including components equity income loss affiliates depreciation amortization expenses internal management reporting presented chief operating decision maker company allocate vast majority indirect production costs research development expenses general administrative expenses well cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits reconciliation total segment revenues consolidated sales follows years ended december segment revenues revenues revenues primarily comprised miscellaneous corporate revenues sales related divested products businesses supply sales consolidated revenues geographic area derived follows years ended december united states europe middle east africa japan reconciliation total segment profits consolidated income continuing operations taxes follows years ended december segment profits profits adjustments unallocated interest income interest expense equity income loss affiliates depreciation amortization acquired research research development expenses net profits primarily comprised miscellaneous corporate profits well operating profits related divested products businesses supply sales adjustments represent elimination effect double counting certain items income expense equity income loss affiliates includes taxes paid joint venture level portion equity income reported segment profits expenses net include expenses corporate manufacturing cost centers miscellaneous income expense net property plant equipment net geographic area located follows december united states europe middle east africa japan company disaggregate assets products services basis internal management reporting therefore information notpresented merck co inc annual report managements report primary responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization establishing internal controls management weighs costs systems benefits believes systems provide staff internal auditors regularly monitors adequacy application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices company periodically conducts managements stewardship program key management financial personnel program reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition ethical business practices program implemented reinforce companys longstanding commitment high ethical standards conduct business independent auditors audited companys consolidated financial statements described report although audits designed purpose forming opinion internal controls accompanying report based audit conducted accordance auditing standards generally accepted united states america includes consideration companys internal controls establish basis determining nature timing extent audit tests performed recommendations internal auditors independent auditors reviewed management control procedures implemented revised appropriate respond recommendations material control weaknesses brought attention management managements opinion year ended december internal control system strong accomplished objectives discussed herein financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included companys filing raymond v gilmartin judy c lewent chairman president executive vice president chief executive officer chief financial officer president human health asia report independent auditors stockholders board directors merck co inc opinion accompanying consolidated balance sheets related consolidated statements income retained earnings comprehensive income cash flows present fairly material respects financial position merck co inc subsidiaries december december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america financial statements responsibility companys management responsibility express opinion financial statements based audits conducted audits statements accordance auditing standards generally accepted united states america require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion discussed note financial statements company adopted statement financial accounting standards goodwill intangible assets effective january florham park new jersey pricewaterhousecoopers llp february merck co inc annual report audit committees report audit committee comprised independent directors met independent auditors management internal auditors assure carrying respective responsibilities audit committee discussed received letter independent auditors confirming independence independent auditors internal auditors full access committee including regular meetings without management present audit committee met independent auditors discuss fees scope results audit work including adequacy internal controls quality financial reporting committee also discussed independent auditors judgments regarding quality acceptability companys accounting principles clarity disclosures degree aggressiveness conservatism accounting principles underlying estimates audit committee reviewed discussed audited financial statements management recommended board directors financial statements included companys filing securities exchange commission heidi g miller thomas e shenk chairperson samuel thier wendell p weeks peter c wendell compensation benefits committees report compensation benefits committee comprised independent directors approves compensation objectives policies employees sets compensation companys executive officers committee seeks ensure rewards closely linked company division team individual performances committee also seeks ensure compensation benefits set levels enable merck attract retain highly qualified employees committee views stock ownership vehicle align interests employees companys stockholders consistent longterm focus inherent companys rdbased pharmaceutical business policy committee make high proportion executive officer compensation dependent longterm performance enhancing stockholder value lawrence bossidy william g bowen chairperson johnnetta b cole william daley william n kelley merck co inc annual report selected financial data merck co inc subsidiaries millions except per share amounts results year sales materials production costs marketing administrative expenses research development expenses acquired research equity income affiliates gains sales businesses income expense net income continuing operations taxes taxes income income continuing operations income discontinued operations net taxes net income basic earnings per common share continuing operations discontinued operations net income earnings per common share assuming dilution continuing operations discontinued operations net income cash dividends declared cash dividends paid per common share capital expenditures depreciation yearend position working capital property plant equipment net total assets longterm debt stockholders equity financial ratios income continuing operations sales net income average total assets yearend statistics average common shares outstanding millions average common shares outstanding assuming dilution millions number stockholders record number employees certain prior year amounts restated reflect results medco health discontinued operations amounts include impact implementation new distribution program us wholesalers restructuring costs related position eliminations amount add result rounding decrease primarily reflects impact spinoff medco health merck co inc annual report table contentstable contents exhibit dear merck colleagues think moment contributions company made society past century think lives saved lengthened significantly improved result efforts think families enjoyed additional years brothers sisters parents children products services reflect lifesaving lifeenhancing role company plays world feel enormous sense pride great sense responsibility ensure organization preserved future generations try never forget medicine people profits profits follow remembered never failed appear george w merck words written many years ago vastly different world yet values embody continue guide company every day around world technical advancements superseded marketing strategies change manufacturing processes pass obsolescence values standards endure although speak different languages represent many cultures united drive best deliver breakthrough medicines integrity honesty shared values make us merck basis success perhaps anything else furthering companys values standards greatest effect future success company values george merck imparted live continue guide actions decisions future generations say us booklet designed assist us making george mercks vision continuing reality discusses standards reflect values guide us daytoday decisionmaking great deal effort part merck employees around world gone creation ask everyone read entire booklet adhere standards model values whenever wherever conduct merck business think find values standards invaluable resource sincerely ray gilmartin chairman president ceotable contents introduction resources relationships customers product service quality honest communication clinical trials postmarketing clinical trials gifts entertainment invitations conferencessymposia fair competition gathering competitive information relationships fellow employees work environment fair treatment health safety workplace harassment sexual harassment relationships shareholders conflicts interest use corporate assets personal use communication tools protection company information accuracy booksrecords insider trading relationships suppliers selection suppliers treatment suppliers relationships communities society corporate responsibility public communications environmental stewardship improper payments use selection agents compliance laws rules regulations boycotts importexport regulations index deferral program amended restated deferred payment directors ' compensation plan offer letter computation ratios earnings fixed charges pages annual report stockholders code conduct list subsidiaries power attorney certified resolution board directors certification ceo certification cfo certification ceo certification cfotable contents table contents introduction resources relationships customers product service quality honest communication clinical trials postmarketing clinical trials gifts entertainment invitations conferencessymposia fair competition gathering competitive information relationships fellow employees work environment fair treatment health safety workplace harassment sexual harassment relationships shareholders conflicts interest use corporate assets personal use communication tools protection company information accuracy booksrecords insider trading relationships suppliers selection suppliers treatment suppliers relationships communities society corporate responsibility public communications environmental stewardship improper payments use selection agents compliance laws regulations boycotts importexport regulations political activities appendix mercks leadership principles index cp corporate policies symbol used throughout code conduct indicate relevant corporate policy numbers policy references provided convenience part code corporate policies viewed intranet httphumresmerckcompolprocmainhtmtable contents purpose merck values standards always formed basis success inspire trust confidence part medical community government officials regulatory agencies financial markets customers patients essential success even important values inspire trust confidence merck employeescreating sense pride desire us achieve great things merck yes care lot results achieve care much achieve comment george w merck medicine people embodies values aspirations sometimes always clear means daytoday activities decisionmaking members merck community booklet aims illustrate values applied standards conduct key stakeholders customers employees shareholders suppliers communities applicability code conduct relevant corporate policies apply everyone conducts business behalf merck including employees executive officers eg chief executive officer chief financial officer controller etc members board directors agents consultants contract labor others handling merck matters exceptional situations warrant waiver companys standards waiver executive officers members board directors may granted board directors board committee waiver must promptly disclosed shareholders accountability us responsible adhering values standards set forth code raising questions uncertain whether standards met violations code may result variety corrective actions cases may result disciplinary action including termination employment availability believe stakeholders entitled know business practices values standards booklet available public accessed via website wwwmerckcom questions concerns please refer resources listed website table contents customers business preserving improving human life animal health actions must measured success achieving goal value ability serve patients benefit appropriate use products services dedicated providing highest level professional excellence health delivery systems strive identify critical needs health care professionals consumers devote resources meeting needs suppliers believe developing mutually beneficial relationships suppliers recognize important partners success treat honesty fairness respect communities society good corporate citizen means comply applicable laws rules regulations also serve society local communities operate plants national international levels supporting programs advance knowledge education improve health care addition priorities support programs protect environment promote art cultural activities foster civic institutions fellow employees ability succeed depends integrity knowledge imagination skill diversity flexibility teamwork merck employees end strive create environment mutual respect encouragement teamworka working environment rewards commitment performance seeks responsive needs employees seek provide workplace atmosphere attracts highly talented people helps achieve full potential us responsible creating climate trust respect promoting productive work environment responsibilities embodied leadership principles know develop know develop business know support develop people communicate shareholders recognize ability meet goals depends maintaining financial performance encourages investment leadingedge research development turn enables us deliver effective products innovative services strive provide honest accurate timely information toour shareholders performance make clear disclosures public reports communications table contents guidelines matter detailed possibly anticipate challenges may face job additional resources use questions business conduct booklet serves guide standards including frequently asked questions intended exhaustive description companys policies standards throughout booklet find shaded boxes contain responses real questions merck employees raised supplementary information number issues may found referring relevant corporate policies find referenced throughout guidelines policies may accessed via intranet may contact human resources department questions fully addressed resources next step discuss questions manager resources also availableincluding specialists legal finance corporate audit human resources departments office ethics adviceline information contacting using resources please see resources listed website use resources need clarification policies assistance dealing gray areas concerned possible violations standards laws regulations many topics dont seem apply concerned booklet companywide global document sections topics may relevant certain functions departments others however may helpful aware business conducted different areas company decision test decision test set criteria use help determine appropriate course action simply ask action legal comply letter standards policies comply spirit standards policies would look newspaper would appear improper make feel embarrassedif unsure contact manager resources listed website guidance need values standards booklet always good reputation integrity honest business practices merck always enjoyed good reputation values standards long source pride employees recognizing operate dynamic rapidly changing business environment could easily lose good name continually reinforce values standards employees ensure integrity remains continuing priority merck employees understand companys expectations suggestion employees decided compile companys basic guidelines business practices one booklet use reference tool new corporate governance initiatives mandate companies code ethics emphasize need booklet questions concerns please refer resources listed website table contents product service quality cp quality means consistently satisfying customers requirements expectations delivering products services highest value timely manner customers include patients health care professionals health care organizations government agencies wholesalers distributors quality improvement areas business product research laboratories patient use products services imperative providing innovative products services improve quality life achievement quality goals objectives depends ability listen respect customer needs every business activity behind schedule great deal pressure may modify manufacturing steps speed production strive streamline manufacturing processes make efficient possible must always go proper channels receive approval new techniques steps may required government regulatory agencies others may required meet quality standards possible steps seem unnecessary could serve critical quality function questionsor make suggestions process might improvedconsult manager head quality operations site taking action honest communication cp lives depend quality products services also quality information provide medical community general public information furnished customers products services including availability delivery must useful accurate supported scientific evidence relevant presented honestly fairly proper means means promotional communications include description uses dosage recommendations must also include unless otherwise required law regulation summary side effects precautions warnings contraindications well effectiveness described indicated uses communicate publicly intent promoting products use product approved use however restrict full proper exchange scientific information concerning product including dissemination research findings scientific communications media sales representative know im supposed encourage promote use products inconsistent product labeling physician starts asking questions use may refer studies doctors also prescribing use generally speaking merck sales representatives must provide directly physicians information inconsistent contained product label advise physician merck recommend use product purposes specified product label however physician desires additional information topic refer request medical services department department authorized certain limited circumstances provide information directly physicians table contents clinical trials clinical trials determine safety efficacy products people volunteer participate studies therefore crucial conduct trials utmost regard health safety participants furthering interests science society detailed standards guidelines available concerning clinical trials product protocols postmarketing clinical trials postmarketing clinical trials help us learn safety efficacy products provide important information practicing physicians thirdparty payers key decisionmakers foster appropriate use merck products also assist gaining wider awareness acceptance products special populations unique geographic locations physician advised competitor providing payment prescription writes products acceptable acceptable practice however may happening doctor participating bona fide post marketing clinical study case may appropriate compensate physician additional workload participating study unrelated prescriptions physician writes gifts entertainment cp cp giving gifts physician customers wish safeguard publics confidence physicians make decisions solely basis patient health provide gifts incentives substantial value physician customers part building relationships may provide occasional gifts long gifts primarily entail benefit patients substantial value gifts may include medical textbooks items serve genuine educational function additionally promotional items nominal value also permissible eg pens notepads calendars etc provided related physicians practice localregional lawyer provide detailed definition nominal value relevant specific location invited wedding important customer culture expected guests bring cash gifts wedding cases cash gifts prohibited consult manager believe exception company policy warranted prior written approval area divisional vice president must obtained chief cardiologist major hospital requested donation equipment hospitals new cardiaccare unit would donation violation business standardsit may appropriate desirable company make contribution improve quality local health care facilities however question must considered regard following would donation conflict local laws ultimate beneficiary donation physician hospital hospital considering adding merck product formulary would donation affect perceived affect decisionmaking process consult manager explore whether donation may made region table contents customers addition physicians also build relationships important customers including health care professionals wholesalers distributors respect customers promotional items nominal value permissible eg pens notepads calendars etc recognize certain cultures may occasion giftgiving substantial nature customary expected decisions situations must carefully weighed prior written approval must obtained area divisional vice president receiving gifts receipt gifts may common context supplier relationships guidelines included ease reference convenience part building relationships may receive occasional gifts provided gift nominal value eg pens notepads calendars etc legal gift neither intended likely perceived others improperly influence business decisions occasionally may times refusing gift would impractical embarrassing rare instances gift substantial value accept gift behalf company report manager turn gift localregional finance director handle disposition government officials employees gifts meals entertainment benefits generally providing gifts meals entertainment benefits government officials employees acceptable company wishes avoid even appearance impropriety additionally laws concerning appropriate gifts entertainment respect groups complex vary country countryand even within country eg local versus national officials therefore consult legal department providing gift invitation kind government employee longtime supplier sent flowers commemorate tenyear anniversary company return flowers supplier returning flowers may impractical may also embarrassing supplier may accept flowers return supplier feel uncomfortable keeping supplier offer gifts regular basis politely advise mercks gifts policy providing accepting meals entertainment means building relationships may provide accept occasional meals social entertainment provided course bona fide business relationship accompaniment educational business discussionfunction legal consistent industry practices likely perceived attempt improperly influence business decisions embarrassing company receive public scrutiny customary country take customers restaurant discuss business drinks acceptable policy acceptable practice ensure entertainment reasonable good taste otherwise appropriate country table contents potential supplier invited attend professional sporting event may attend sporting event appropriate excessive supplier attending thus available discuss business may acceptable attend important however accepting invitation neither intended likely perceived attempt improperly influence business decision example occasional unsolicited tickets regularseason sporting events would acceptable playoffs quarterfinals semifinals require scrutiny tickets finals championship events eg world cup olympics wimbledon would considered excessive localregional lawyer provide detailed explanation inappropriate excessive relevant specific location invitations conferencessymposia cp cp committed conducting participating educational programs share medical scientific information recognize importance ensuring activities undertaken appropriate professional manner ultimate goal improving patient care however standards necessarily take account local legal requirements restrictive local laws exist take precedence primary focus scientificeducational meetings must agenda appropriate participants scientific agenda dominate social activities location selected basis participant travel convenience cost appropriateness type meeting audience fund travel spouses companions attendees exceptions policy require prior written approval area divisional vice president funding travel expenses important opinion leader speaking mercksponsored conference would like bring spouse expense permitted spouse companion may travel conference provided companys expense means travel lodging meals costs associated spouses presence borne company however spouses companions permitted attend sessions meetings official business discussed unless invited sponsors conference honor physicians request issue two economyclass tickets place one businessclass ticket attend conference may done invitation extended physician company cover expenses directly associated invitees attendance pay physician involved approval process new drugs attend meeting would ultimately paying regulatory agency approves drugsthe laws regulations governing activities complex vary depending variety factors including physician government employee physician decisionmaker regulatory approval process merck product registration pending due complexity legal department must consulted advance generally answer would individuals attendance greater public good may situations permitted expenses handled appropriate legal manner table contents fair competition cp believe customers society whole benefit fair free open markets therefore compete merits products services make agreements competitors fix prices restrain trade principles fair competition require share exchange price bid information competitors includes pricing policies discounts promotions royalties warranties terms conditions sale competitor volunteers information whether trade association meeting physicians waiting room terminate conversation immediately bring situation attention legal department exchange may intended innocently also could create appearance pricefixing bidrigging compete aggressively every market every customer make agreementsor general understandingswith competitors concerning customers distributors territories demand suppliers business us order retain merck business mischaracterize distort products services competitor standards fair competition also matter law virtually every country operate additional legal requirements must comply every manager must ensure employees involved marketing sales purchasing aware letter spirit standards applicable competition laws attending trade association meeting several members discussing pricing strategy issues pricing strategy discussed among competitors possibility pricefixing collusion could occur perceived occurred many countries prohibit discussion pricing among competitors reason find situation must excuse meeting immediately promptly advise legal department observed gathering competitive information compete fairly honestly gather market information misrepresentation theft invasion privacy coercion additional rules regarding informationgathering may apply government bids please contact manager legal department information hired employee competitor much information allowed volunteer former employer must allow employee volunteer ask nonpublic information former employer ask would comfortable former merck employee shared information competitor additionally legal implications relating disclosure confidential information companies clarification consult manager legal department questions concerns please refer resources listed websitetable contents work environment cp seek provide work environment attract retain highly talented people help achieve full potential us responsible creating climate trust respect promoting productive work environment responsibilities described leadership principles see serve foundation human resources policies practices processes leadership principles spell specific behaviors expected us additionally respect privacy dignity fellow employees safeguard confidentiality employee records encourage open communication receptive ideas concerns others offer receive feedback constructively fair treatment cp meet longterm growth efficiency requirements must build organization responds quickly change one people achieve full potential differences backgrounds experiences perspectives talents fundamental strength global company treat individual fairly recruit select train pay based merit experience workrelated criteria information contact human resources representative corporate human resources diversity department acceptable stipulate gender age open position business justification advertising positions based gender age treating people fairly hiring based solely job related criteria right thing smart business health safety cp conduct operations highest regard safety health employees protection general public us responsible complying safety rules regulations taking necessary precautions protect colleagues must report accidents take action correct unsafe practices conditions goal continuously improving performance central safety industrial hygiene answer specific questions merck safety standards really necessary report minor accident dont want jeopardize plants safety record maintain safety performance excellence strive accidentfree environment must report accidents matter minor work eliminate unsafe practices conditions reporting even minor accidents important helps us identify hazards take corrective action serious injuries occur uncover serious unsafe condition shutdown operationsin circumstances believe imminent danger condition exists delay would jeopardize safety authorized shutdown operations shutdown operations extremely disruptive response safety problem however sometimes may required order protect people facility serious hazard merck expects employees discover unsafe conditions report supervisor conditions remedied effective manner table contents drug alcohol abuse use illegal drugs alcohol abuse create serious health safety risks workplace possession sale use illegal drugs company time property companysponsored events prohibited similarly impairment alcohol conducting merck business companysponsored events also prohibited important cases drug alcohol abuse brought managements attention immediately information resources location deal substance abuse please see resources listed website workplace harassment cp strive maintain environment free harassment employees respected workplace harassment defined action creates intimidating hostile offensive work environment examples include limited disparaging comments based race gender religion nationality sexual harassment sexual harassment form workplace harassment sexual nature affects dignity men women work sexual harassment includes limited demanding sexual considerations exchange job benefits threatening taking adverse employment actions sexual favors granted unwelcome physical contact feel harassed inform offender action unwelcome comfortable direct approach fails correct problem discuss matter supervisor human resources refer resources listed website permissible date subordinate consensual relationship unacceptable romantic relationship someone direct indirect reporting relationship relationships inevitably damage morale disrupt productivity workplace inherent conflict interest managing someone romantic relationship even acting impartially relationship likely perceived negatively therefore must immediately disclose relationship manager human resources dating colleague acceptable yes provided direct indirect reporting relationship common country make jokes certain nationalities acceptable jesting officehumor important element life inside outside office however acceptable make fun expense others based national ethnic differences offensive behavior even intended contributes environment intolerance sure joke comment appropriate refrain communicating questions concerns please refer resources listed website table contents conflicts interest cp responsibility shareholders make decisions strictly basis mercks best interests without regard personal concerns potential conflict interest arises become involved directly indirectly outside activities could impair perceived impair business judgment examples actual potential conflicts interest include personal financial interest customer distributor competitor supplier close family member eg spouse child sibling parent inlaw work customer distributor competitor supplier receiving form compensation customer distributor competitor supplier personal interest potential gain company transactions key addressing conflicts interest full disclosure often disclosing potential conflict company action required believe may potential conflict interest must discuss situation manager certain employees including directors officers executives designated employees must file annual conflict interest certifications describing actual potential conflicts interest company loans employees particularly sensitive subject specific scrutiny company loans executive officers members board directors prohibited unless already existence july husband works competitor need inform company potential conflict interest must disclosed manager potential conflict disclosed company take steps properly address situation necessary example working product competes product work merck company may elect assign another product fianc works one distributors since family member associated merck business must disclose manager close relationships fianc could also considered potential conflict interest determine may true case discuss matter manageri shares stock british telecom since bt provides phone services merck must report conflict interest investment representing less percent outstanding shares publicly owned company british telecom investment constitutes less percent value investments would considered potential conflict interest policy table contents use corporate assets cp shareholders right expect companys assets properly maintained used economical efficient manner general rule use company equipment resources excluding communications tools see personal use however may times personal use corporate resources acceptable questions situations discuss manager support company working advanced chemistry degree may use company laboratory equipment weekend studies due health safety risks personal use company laboratory equipment permitted believe extraordinary circumstances warrant exception discuss situation manager personal use communication tools company encourages us make efficient effective use communications tools email intranet internet voicemail telephones photocopiers fax machines accomplish business objectives tools also allow us efficiently accomplish personal activities use generally permitted provided adverse effect productivity work environment usage also must conform existing standards policies regarding communication tools general guidelines various communication tools include telephones use common sense good judgment using company telephones personal business quick call home acceptable lengthy overseas calls acceptable faxes photocopiers personal use acceptable provided infrequent insubstantial photocopying tax return acceptable copying announcements sports club acceptable internet email personal use interfere work productivity exceed nominal cost company use common sense good judgment internet shopping lunch hour acceptable spending afternoon surfing web acceptable particular division location may adopted restrictive guidelines concerning personal use communication tools cases restrictive standard applies cases personal use communication tools subject discretion manager process buying house must immediately fax three document agent may use company fax must leave office find public fax use good judgment case use company fax personal use company fax machine acceptable provided usage insubstantial infrequent questions situations discuss manageri going holiday thailand family acceptable use internet check local weather yes employees may use internet email systems personal activities interfere productivity work environment please note following examples inappropriate use internet email systems strictly forbidden times table contents downloading transmitting pornographic sexist racially ethnically insensitive material posting opinions views regard company companys business internet newsgroups chat rooms bulletin boards etc unless specifically authorized company conducting private business activity internet email systems information contact corporate computer resources department protection company cp information cp information important company asset must protected loss confidential information extremely damaging competitive position examples confidential information include limited pricing formulations research results manufacturing methods financial data marketing sales strategies plans disclose confidential company information without valid business purpose proper authorization management us responsible protecting confidentiality company information general guidelines protecting confidential company information include discussing sensitive company business public using password protection computer files securing sensitive information locked files cabinets securing sensitive information laptop computers traveling exercising caution using speakerphones cellular phones even leave employment merck obligated maintain confidentiality merck information return documents files including electronicallystored information overheard merck employees discussing company business airplane anything believe information discussed sensitive confidential advise parties overheard every merck employee responsibility ensure confidential proprietary information disclosed public using home computer came across chat room sensitive merck information divulged disclosure confidential company information strictly forbidden seriously harms company trying achieve business objectives discuss observation manager may also call adviceline contact office ethics advising observations questions concerns please refer resources listed website table contents accuracy booksrecords cp make decisions based information recorded every level company incomplete inaccurate information may lead poor decisions negative consequences example improper recording revenues expenses leads misrepresentation companys financial position illegal incomplete inaccurate manufacturing documents could jeopardize supply product violate regulations accuracy public disclosures must make certain disclosures made company periodic reports documents filed governmental agencies public communications made company full fair accurate timely understandable obligation applies employees including financial executives responsibility preparation reports including drafting reviewing signing certifying information contained therein requires operating environment open communication compromising proprietary confidentiality concerns concerns aspect financial disclosures discuss concerns manager finance organization legal department office ethics adviceline employee contacted another employee raising questions concerns questionable accounting auditing matters must immediately report concerns office ethics must record information honestly accurately includes limited expenses revenues research test results production quality data corporate information financial transactions payments must authorized recorded strict compliance corporate accounting methods required cooperation internal external auditors contact divisional controller corporate audit group client director questions concerning proper recording financial transactions december money left annual budget acceptable prepay next years activities using years budget activities payments must matched period event occurs year payment recorded taking place year activity set next year payment must charged next years budget accounts table contents sales order came confirmed two days books closed acceptable include unconfirmed sales earlier period sale officially taken place confirmed goods shipped misrepresentation include unconfirmed sales earlier period delay processing sales orders next period help us attain income targets period sales orders received must processed accordance standard operating procedures transaction inappropriate manipulate sales orders processing next financial period insider trading cp merck strives preserve fair open markets buying selling companys securities may buy sell merck securities basis nonpublic material information material inside information information reasonable investor would consider important making investment decisions examples may include knowledge acquisitions divestitures new products processes financial information corporate earnings restrictions apply nonpublic material information companies learn capacity merck employees also prohibited disclosing nonpublic material information others inside outside merck without legitimate business reason proper management authorization inside information must refrain trading affected securities beginning second full trading day public disclosure information doubt whether purchase sale securities would violate insider trading standards please consult legal department questions concerns please refer resources listed website table contents selection suppliers cp select goods services best contribute longterm well merck choose suppliers based price quality delivery service diversity reputation factors including environmental business practices also may taken consideration merck condemns use forced labor exploitative child labor expects suppliers respect principle well suspect one suppliers using child labor discuss observation manager may also contact adviceline prefer may send note office ethics advising observations treatment suppliers treat suppliers subcontractors fairness integrity respect terms conditions agreements suppliers honor commitments strive pay time careful protect confidential proprietary information suppliers ensure suppliers given opportunity compete business obtain competitive bids feasible acceptable copy company software home computer would used company business generally acceptable must respect terms softwarelicensing agreements may limit number machines software may installed determine whether would acceptable particular software consult corporate computer resources departmenttable contents corporate responsibility cp merck believes essential component corporate responsibility provide support charitable philanthropic organizations benefit society local plant community international level merck makes cash contributions directly merck company foundation donates products inkind services qualified organizations programs address needs society support mercks overall business mission enhance health philanthropic outreach merck guided two strategic priorities worldwide advance scientific knowledge education improve health care merck supports initiatives address selected health care issues funding donates mectizan treat river blindness merck medicines address health care needs developing countries addition priorities funding also provided support programs protect environment promote art cultural activities foster civic institutions appropriate merck provides assistance response major disasters medical emergencies information contact corporate office contributions whitehouse station merck company foundation merck company foundation usbased private charitable foundation established merck foundation funded entirely company mercks chief source funding support qualified nonprofit charitable organizations mission foundation advance biomedical science training education improve health care worldwide well support programs arts civics environment since inception us million contributed foundation educational health social services civic cultural environmental charitable organizations public communications cp communications news media potentially important reflect upon companys image business vital communications company consistent regulatory legal obligations fulfilled communications must accurate responsible keeping mercks medical legal policies media public requests information referred coordinated public affairs make presentation conference press coverage likely respond im approached media following presentation journalists often approach scientists executives make presentations professional forums press coverage likely result public affairs advised advance questions answers prepared feel free clarify reporter anything formally presented meeting questions go beyond formally presented referred public affairs copies slides given without prior clearance merck research laboratories public affairs could jeopardize scientific publication processif questions concerns please refer resources listed website table contents environmental stewardship cp responsibility protect environment among highest priorities comply letter spirit environmental laws regulations respect environment every country operate provide consumers information help handle products environmentally responsible way central safety environment answer specific questions mercks environmental standards check safety environment web site mmdmerckcomse availability new manual environmental standards laws country prohibit dumping waste onsite dispose merck waste way disposal method must accordance mercks environmental standards specific practices vary depending type waste merck developed best practice global environmental standards facilities cases standards require actions exceed laws individual countries would allow site services manager responsibility buying replacements everything light bulbs equipment mercks goal continuous improvement mean always select environmentallybeneficial option necessarily sometimes cost environmentallybeneficial option disproportionate benefit obtained generally however cost differential options significant real environmental benefit result environmentally beneficial option selected environmental commitments provide inherent protection way design operate facilities processes ensure trust communities promote resource conservation waste minimization minimization release chemicals environment provide employees customers suppliers public authorities communities appropriate information informed decisionmaking continuously improve table contents improper payments cp promote good government fair impartial administration laws may promise offer make payment money anything value government official political party intent induce favorable business treatment improperly affect government decisions standards necessarily take account local legal requirements restrictive local laws exist take precedence general consider ordinary reasonable business entertainment gifts insubstantial value customary legal local market improper seek advice legal department uncertainty propriety legality action additional information refer gifts entertainment policy told pay gratuity minor official clear products customs company provide gratuities officials ensure execution official duties seek advice manager legal department use selection agents engage reputable qualified individuals firms consultants agents representatives distributors compensation arrangements reasonable relation services performed integrity performance merck standard employees agents alike wherever business ignorance standard never acceptable excuse improper behavior acceptable improper behavior rationalized companys best interest act impropriety advances interests company company ensure agents comply mercks standards responsibility employee making recommendation conduct research ensure agent reputable minimum include research parties multinational companies agent worked past information reflected approval memorandum submitted management compliance laws rules regulations cp good corporate citizen means comply applicable laws rules regulations managers responsible communicating relevant rules regulations employees assistance contact legal department boycotts usbased company merck operations including foreign subsidiaries must comply us laws pertaining foreign boycotts laws primarily refer arab boycott israel however time time boycott issues may arise variety activities prohibited antiboycott laws including furnishing information mercks persons past present prospective relationship boycotted countries blacklisted companies paying honoring confirming letters credit containing boycott provisionsif questions concerns please refer resources listed website table contents law also requires certain requests boycott information reported us government antiboycott legislation complex requests directed immediately legal department importexport regulations may export sell drugs without proper approvals merck research laboratories clinical regulatory development review committee addition drugs must first meet legal requirements producing country countries drugs would exported may import export countries us embargo eg sudan iran libya cuba may import export certain individuals organizations contact prohibited us government agencies justify sending medicine people need live places political favor united states return right operate united states obligated comply applicable united states laws apply operationswhether agree laws please note us laws pertaining export controls apply merck operations outside us country operate illegal comply us trade embargo regulations certain countries handle situation transnational compliance embargo regulations complex issue varies country country concerns must directed legal department political activities good corporate citizenship requires unfairly illegally influence political process communities operate due complexity diversity laws regulations governing corporate political activities political contributions related activities may undertaken prior approval chief executive officer private citizens may participate political process including contributing candidates parties choice however may use company time property resources personal political activities table contents table contents table contents index accidents see safety alcohol books records boycotts clinical trials protocols competitors competitive information fair competition computers software confidential information confidentiality commitment employees conflict interest corporate assets use dating coworkers discrimination see fair treatment drugs illegal email see internet employment equal relatives entertainment accepting offering see gifts environment work fair treatment fraternization gifts conferencessymposia giving receiving meals entertainment tickets harassment insider trading internet invitations see gifts kickbacks media office equipment personal use political activities quality product service regulations importexport relationships communities society family personal fellow employees shareholders suppliers romantic relationships safety sexual harassment shareholders socializing coworkers see fraternization stock companies suppliers see relationships suppliers tickets see gifts exhibit merck co inc subsidiaries following list subsidiaries company business name stated country state name incorporation abello farmacia sl spain algonquin sarl luxembourg amrad pharmaceuticals pty ltd australia aventis pasteur msd denmark aventis pasteur msd gestion sa france aventis pasteur msd gmbh austria aventis pasteur msd gmbh germany aventis pasteur msd ltd great britain aventis pasteur msd ltd ireland aventis pasteur msd nvsa belgium aventis pasteur msd sa spain aventis pasteur msd spa italy aventis pasteur msd snc france banyu pharmaceutical company ltd japan banyuasc co ltd japan blue jay investments cv netherlands brc ltd bermuda british united turkeys limited great britain centra medicamenta otc spa italy charles e frosst new zealand ltd new zealand charles e frosst uk limited great britain chibret denmark chibret pharmazeutische gmbh germany chippewa holdings llc delaware cloverleaf international holdings sa luxembourg cm delaware llc delaware comsort inc delaware coordinated patient care scandinavia norway crosswinds bv netherlands dieckmann arzneimittel gmbh germany european insurance risk excess limited ireland farmacoxcompanhia farmaceutica lda portugal farmasixprodutos farmaceuticos lda portugal financiere msd sas france fontelaborprodutos farmaceuticos lda portugal fregenal holdings sa panama frosst iberica sa spain frosst laboratories inc delaware frosst portuguesa produtos farmaceuticos lda portugal hangzhou msd pharmaceutical company limited chinacountry state name incorporation hawk falcon llc delaware hubbard isa llc delaware hubbard isa sas france infodoc norway infodoc international norway international indemnity ltd bermuda istituto di richerche di biologia molecolare spa italy istituto gentili spainc italydelaware johnson johnson merck consumer pharmaceuticals company new jersey johnson johnsonmsd consumer pharmaceuticals limited great britain kbi inc delaware kbi sub inc delaware kbie inc delaware kbip inc delaware kiinteisto oy viistotie finland laboratoires martinjohnson johnsonmsd sas france laboratoires merck sharp dohmechibret snc france laboratorios abello sa spain laboratorios biopat sa spain laboratorios chibret sa spain laboratorios frosst sa spain laboratorios neurogard sa spain laboratorios quimicofarmaceuticos chibret lda portugal maple leaf holdings srl barbados mcm vaccine co pennsylvania medco de mexico managed care de rl de cv mexico medco holdings de rl de cv mexico medco managed care sl spain medco servicios de mexico de rl de cv mexico merck company incorporated delaware merck borinquen holdings inc delaware merck capital resources inc delaware merck capital ventures llc delaware merck cardiovascular health company nevada merck enterprises canada ltd canada merck finance co inc delaware merck foreign sales corporation ltd bermuda merck frosst canada co canada merck frosst canada ltd canada merck hamilton inc california merck holdings ii corp delaware merck holdings inc delaware merck institute vaccinology delaware merck investment co inc delaware merck liability management company delaware merck lmc cash management bermuda ltd bermuda merck lmc cash management inc delaware merck resource management inc delaware country state name incorporation merck respiratory health company nevada merck sh inc delaware merck sharp dohme france merck sharp dohme lebanon sal lebanon merck sharp dohme argentina inc delaware merck sharp dohme asia limited hong kong merck sharp dohme australia pty limited australia merck sharp dohme china limited hong kong merck sharp dohme europe inc delaware merck sharp dohme holdings limited great britain merck sharp dohme ia corp delaware merck sharp dohme international limited bermuda merck sharp dohme ireland ltd bermuda merck sharp dohme israel company ltd israel merck sharp dohme italia spa italy merck sharp dohme middle east limited cyprus merck sharp dohme new zealand limited new zealand merck sharp dohme panama sa panama merck sharp dohme philippines inc philippines merck sharp dohme puerto rico ltd bermuda merck sharp dohme singapore ltd bermuda merck sharp dohme sweden ab sweden merck sharp dohme asia pacific services pte ltd singapore merck sharp dohme bv netherlands merck sharp dohme chibret ag switzerland merck sharp dohme doo croatia merck sharp dohme de espana sa spain merck sharp dohme de mexico sa de cv mexico merck sharp dohme de venezuela srl venezuela merck sharp dohme farmaceutica ltda brazil merck sharp dohme finance europe limited great britain merck sharp dohme gmbh austria merck sharp dohme holdings de mexico sa de cv mexico merck sharp dohme idea inc switzerland merck sharp dohme industria quimica e veterinaria limitada brazil merck sharp dohme inovativna zdravila doo slovenia merck sharp dohme international services bv netherlands merck sharp dohme ireland human health ltd ireland merck sharp dohme sland hf iceland merck sharp dohme llc russian federation merck sharp dohme limited great britain merck sharp dohme pakistan limited pakistan merck sharp dohme overseas finance nv neth antilles merck sharp dohme peru srl peru merck sharp dohme quimica de puerto rico inc delaware merck sharp dohme de rl de cv mexico merck sharp dohme sa morocco merck sharp dohme tunisie sarl tunisia country state name incorporation merck sharp dohme limitada portugal merck sharp dohme ilaclari limited sirketi turkey merck technology us company inc nevada merck ventures inc delaware merial animal health ltd great britain merial gmbh germany merial japan ltd japan merial inc delaware merial italia spa italy merial laboratorios sa spain merial limitedllc great britaindelaware merial sas france msd japan co ltd japan msd nippon holdings bv netherlands msd norge norway msd proprietary limited south africa msd thailand ltd thailand msd chibropharm gmbh germany msd finance bv netherlands msd international holdings inc delaware msd ireland holdings sa luxembourg msd ireland investment ltd bermuda msd korea ltd koreadelaware msd lakemedel scandinavia aktiebolog sweden msd latin america services ltd bermuda msd magyarorszg kereskedelmi szolgltat kft hungary msd overseas manufacturing co ireland ireland msd overseas manufacturing co bermuda msd pembroke ltd bermuda msd polska sp zoo poland msd sharp dohme gmbh germany msd somerset ltd bermuda msd technology singapore pte ltd singapore msd technology lp delaware msd unterstutzungskasse gmbh germany msd ventures singapore pte ltd singapore msd warwick manufacturing ltd bermuda msdessex gmbh switzerland msdsp ltd great britain msp distribution services c llc nevada msp distribution services r llc nevada msp marketing services c llc nevada msp marketing services r llc nevada msp singapore company llc delaware msp singaporesub llc delaware msp technology us company llc delaware neopharmed spa italy nippon merckbanyu co ltd japan country state name incorporation pasteur vaccins sa france readington holdings inc new jersey readington investments inc new jersey rosetta inpharmatics llc delaware ruskin limited bermuda sharp dohme sa spain stellarx inc nevada suomen msd oy finland telerx marketing inc pennsylvania msd foundation limited great britain thomas morson son limited great britain tradewinds manufacturing srl barbados transrow manufacturing ltd bermuda uab merck sharp dohme lithuania varipharm arzneimittel gmbh germany woelm pharma gmbh co arzneimittelvertrieb ohg germany woelm pharma gmbh co ohg germany woelm pharma verwaltungs gmbh germany less exhibit power attorney undersigned hereby appoint celia colbert kenneth c frazier severally hisher true lawful attorney attorneys execute behalf undersigned whether behalf company officer director thereof attesting seal company otherwise annual report merck co inc fiscal year ended december securities exchange act including amendments thereto